A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users
Phase: PHASE3
Conditions: Anaemia
Sponsor: GlaxoSmithKline

2015N266251_02 
CONFIDENTIAL 
 
GlaxoSmithKline group of companies 
 
PHI201754 
 
- 1 - 
 
TITLE PAGE 
 
Division：Worldwide Development 
Information Type： Clinical Protocol 
 
 
Title：A 52-week, Phase III, double-blind, active-controlled, parallel-group, multi-center study to 
evaluate efficacy and safety of daprodustat compared to darbepoetin alfa in Japanese hemodialysis-
dependent subjects with anemia associated with chronic kidney disease who are currently ESA users. 
Compound Number： 
Daprodustat 
Development Phase 
III 
Effective Date： 
 
19-Jul-2017 
 
Protocol Amendment Number： 
02 
 
Author(s)： 
 
  
 
Revision Chronology： 
GlaxoSmithKline Document 
Number 
Date 
Version 
2015N266251_00 
19-JUL-2016 
First version 
2015N266251_01 
08-MAR-2017 
Amendment 01 
Clarification of the timing of eligibility assessment regarding exclusion criteria, addition of the 
prohibited medication, and correction of adverse events of special interest 
2015N266251_02 
19-JUL-2017 
Amendment 02 
Change for definition of screen failures, clarification of the withdrawal/dropout criteria for prohibited 
medication, clarification of definition of overdose of daprodustat, update of AESI, addition of details 
of sensitivity analyses for primary efficacy analysis and description adjustment, update of risk 
assessment (Appendix 2) , and correction of erroneous description  
 
 
Copyright 2016 the GlaxoSmithKline group of companies.  All rights reserved.  Unauthorised 
copying or use of this information is prohibited. 
 
PPD
PPD

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 2 - 
Sponsor Signatory: 
 
 
 
 
Kihito Takahashi 
Director, 
Japan Development and Medical Affairs (JDMA), 
GlaxoSmithKline K. K. 
 
The IMMS document approved is as follows: 
  Unique ID: 090033ec8416fd56 
  System Version:1.0 
  Effective Date: 19 Jul 2017 
 
Date 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 3 - 
MEDICAL MONITOR/SPONSOR INFORMATION PAGE 
 
Medical Monitor/SAE Contact Information: 
Role 
Name 
Day Time 
Phone 
Number 
Fax Number 
Site Address 
Medical Monitor 
 
M.D., Ph.D. 
GlaxoSmithKline K.K.  
6-15, Sendagaya 4-chome, 
Shibuya-ku, Tokyo 151-8566 
JAPAN 
 
SAE contact  
information 
Person in charge 
of daprodustat 
Clinical 
Operations dept.  
GlaxoSmithKline K.K.  
6-15, Sendagaya 4-chome, 
Shibuya-ku, Tokyo 151-8566 
JAPAN 
 
 
Emergency Contact 
Emergency Contact (Mon to Fri 10am to 6pm, except for national holiday and year-end and New Year 
holidays) 
Person in charge of daprodustat, Clinical Operations dept. R&D, Glaxo Smith Kline K.K 
TEL: 
FAX: 
 
Emergency Contact at night and holiday (Mon to Fri 6pm to 10am, Sat, Sun, national holiday and 
year-end and New Year holidays) 
BI Medical Inc. 
Responsible Person: 
 
TEL: 
(toll free) 
FAX: 
(toll free) 
 
Sponsor Legal Registered Address: 
6-15, Sendagaya 4-chome, Shibuya-ku, Tokyo 151-8566 JAPAN 
 
 
 
PPD
PPD
PPD
PPD
PPD

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 4 - 
INVESTIGATOR PROTOCOL AGREEMENT PAGE 
 
• 
I confirm agreement to conduct the study in compliance with the protocol and the amended 
content. 
• 
I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or 
supervise the described study. 
• 
I agree to ensure that all associates, colleagues and employees assisting in the conduct of the 
study are informed about their obligations. Mechanisms are in place to ensure that site staff 
receives the appropriate information throughout the study. 
• 
 
 
Investigator Name: 
 
 
Investigator Signature 
 
 
Date 
 
 
 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
5 
 
TABLE OF CONTENTS 
Page 
1. 
PROTOCOL SYNOPSIS FOR STUDY PHI201754 ........................................................ 9 
2. 
INTRODUCTION ............................................................................................................ 13 
2.1. 
Study Rationale .................................................................................................... 13 
2.2. 
Background .......................................................................................................... 13 
3. 
OBJECTIVES AND ENDPOINTS .................................................................................. 14 
4. 
STUDY DESIGN ............................................................................................................. 16 
4.1. 
Overall Design ...................................................................................................... 16 
4.2. 
Treatment Groups and Study Periods ............................................................... 16 
4.3. 
Study Subjects and Number of Subjects .......................................................... 17 
4.4. 
Rationale for Study Design ................................................................................. 17 
4.5. 
Rationale for Dose Levels ................................................................................... 18 
4.6. 
Benefit: Risk Assessment................................................................................... 19 
4.6.1. 
Risk Assessment ........................................................................................ 19 
4.6.2. 
Benefit Assessment .................................................................................... 19 
4.6.3. 
Overall Benefit: Risk Conclusion .............................................................. 20 
5. 
SUBJECT SELECTION AND WITHDRAWAL CRITERIA ........................................... 21 
5.1. 
Inclusion Criteria.................................................................................................. 21 
5.2. 
Exclusion Criteria ................................................................................................ 22 
5.3. 
Screening Failures ............................................................................................... 23 
5.4. 
Permanent discontinuation of study treatment and study withdrawal ......... 24 
5.4.1. 
Liver Chemistry Stopping Criteria............................................................. 25 
5.4.1.1. 
Study Treatment Restart or Rechallenge......................................... 26 
5.5. 
Subject and Study Completion .......................................................................... 26 
6. 
STUDY TREATMENTS .................................................................................................. 27 
6.1. 
Investigational Product and Other Study Treatment ....................................... 27 
6.2. 
Medical Device ..................................................................................................... 28 
6.3. 
Treatment Assignment ........................................................................................ 28 
6.4. 
Administration Schedule (Starting Dose, Dose Adjustment, and 
Dosing Frequency) .............................................................................................. 29 
6.4.1. 
Daprodustat ................................................................................................. 29 
6.4.1.1. 
Starting Dose ...................................................................................... 29 
6.4.1.2. 
Maintenance Dose .............................................................................. 29 
6.4.2. 
Darbepoetin Alfa ......................................................................................... 30 
6.4.2.1. 
Dose Conversion ................................................................................ 30 
6.4.2.2. 
Maintenance Dose .............................................................................. 31 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
6 
 
6.5. 
Blinding ................................................................................................................. 31 
6.6. 
Packaging and Labeling ...................................................................................... 32 
6.7. 
Preparation/Handling/Storage/Accountability .................................................. 32 
6.8. 
Compliance with Study Treatment Administration .......................................... 33 
6.9. 
Treatment of Study Treatment Overdose .......................................................... 33 
6.10. 
Treatment after the End of the Study ................................................................ 34 
6.11. 
Concomitant Medications and Non-Drug Therapies ....................................... 34 
6.11.1. 
Permitted Medications and Non-Drug Therapies .................................... 34 
6.11.2. 
Prohibited Medications and Non-Drug Therapies ................................... 34 
6.12. 
Supplemental Iron Therapy ................................................................................ 34 
7. 
Study Assessments and Procedures ......................................................................... 35 
7.1. 
Time and Events Table ........................................................................................ 35 
7.2. 
Screening and Critical Baseline Assessments ................................................ 39 
7.3. 
Efficacy ................................................................................................................. 39 
7.4. 
Safety .................................................................................................................... 39 
7.4.1. 
Adverse Events (AE) and Serious Adverse Events (SAEs) .................... 39 
7.4.1.1. 
Time period and Frequency for collecting AE and SAE 
information .......................................................................................... 39 
7.4.1.2. 
Method of Detecting AEs and SAEs ................................................. 40 
7.4.1.3. 
Follow-up of AEs and SAEs .............................................................. 40 
7.4.1.4. 
Cardiovascular and Death Events .................................................... 40 
7.4.1.5. 
Regulatory Reporting Requirements for SAEs ............................... 41 
7.4.2. 
Adverse Events of Special Interest ........................................................... 41 
7.4.3. 
Pregnancy .................................................................................................... 41 
7.4.4. 
Medical Device Incidents (Including Malfunctions) ................................ 42 
7.4.4.1. 
Time Period for Detecting Medical Device Incidents...................... 42 
7.4.4.2. 
Follow-up of Medical Device Incidents ............................................ 42 
7.4.4.3. 
Prompt Reporting of Medical Device Incidents to GSK ................. 42 
7.4.5. 
Vital Signs/Height/Weight .......................................................................... 43 
7.4.6. 
Electrocardiogram (ECG) ........................................................................... 43 
7.4.7. 
Clinical Laboratory Assessments ............................................................. 43 
7.4.8. 
Ophthalmology ............................................................................................ 44 
7.5. 
Pharmacokinetics ................................................................................................ 44 
7.6. 
Genetics ................................................................................................................ 45 
7.7. 
Patient Reported Outcome (PRO) ...................................................................... 45 
7.7.1. 
Health Related Quality of Life (SF-36) ....................................................... 45 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
7 
 
7.7.2. 
EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L)/ 
EuroQol Visual Analogue Scale (EQ-VAS) ............................................... 45 
8. 
DATA MANAGEMENT .................................................................................................. 46 
9. 
STATISTICAL CONSIDERATIONS AND DATA ANALYSES ..................................... 46 
9.1. 
Hypotheses ........................................................................................................... 46 
9.2. 
Sample Size Considerations .............................................................................. 47 
9.2.1. 
Sample Size Assumptions ......................................................................... 47 
9.2.2. 
Sample Size Sensitivity .............................................................................. 47 
9.2.3. 
Sample Size Re-estimation or Adjustment............................................... 47 
9.3. 
Data Analysis Considerations ............................................................................ 47 
9.3.1. 
Analysis Populations .................................................................................. 47 
9.3.2. 
Interim Analysis .......................................................................................... 48 
9.3.3. 
Adjustment for Multiplicity ......................................................................... 48 
9.4. 
Key Elements of Analysis Plan .......................................................................... 48 
9.4.1. 
Primary Efficacy Analysis .......................................................................... 48 
9.4.2. 
Principal Secondary Efficacy Analysis ..................................................... 49 
9.4.3. 
Other Secondary Efficacy Analyses ......................................................... 49 
9.4.4. 
Safety Analyses ........................................................................................... 49 
9.4.4.1. 
Exposure ............................................................................................. 50 
9.4.4.2. 
Adverse Events ................................................................................... 50 
9.4.4.3. 
Other Safety Parameters ................................................................... 50 
9.4.5. 
Pharmacokinetics Analyses ...................................................................... 50 
9.4.6. 
PRO Data Analysis ...................................................................................... 50 
10. STUDY GOVERNANCE CONSIDERATIONS .............................................................. 51 
10.1. 
Posting of Information on Publicly Available Clinical Trial Registers ........... 51 
10.2. 
Regulatory and Ethical Considerations, Including the Informed 
Consent Process.................................................................................................. 51 
10.3. 
Quality Control (Study Monitoring) .................................................................... 52 
10.4. 
Quality Assurance ............................................................................................... 52 
10.5. 
Study and Site Closure ....................................................................................... 52 
10.6. 
Records Retention ............................................................................................... 53 
10.7. 
Provision of Study Results to Investigators, Posting of Information 
on Publically Available Clinical Trials Registers and Publicatio.................... 53 
10.8. 
Study Period ......................................................................................................... 54 
10.9. 
Study Administrative Structure .......................................................................... 54 
11. REFERENCES ............................................................................................................... 55 
12. APPENDICES ................................................................................................................ 56 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
8 
 
12.1. 
Appendix 1: Abbreviations and Trademarks .................................................... 56 
12.2. 
Appendix 2:  Risk Assessment ......................................................................... 58 
12.3. 
Appendix 3: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of reproductive potential ............................................. 64 
12.4. 
Appendix 4: Collection of Pregnancy Information ........................................... 65 
12.5. 
Appendix 5: Liver Safety Required Actions and Follow up 
Assessments ........................................................................................................ 66 
12.6. 
Appendix 6: Definition of and Procedures for Recording, Evaluating, 
Follow-Up and Reporting of Adverse Events ................................................... 69 
12.6.1. 
Definition of Adverse Events ..................................................................... 69 
12.6.2. 
Definition of Serious Adverse Events ....................................................... 70 
12.6.3. 
Definition of Cardiovascular Events ......................................................... 71 
12.6.4. 
Recording of AEs and SAEs ...................................................................... 71 
12.6.5. 
Evaluating AEs and SAEs .......................................................................... 72 
12.6.6. 
Reporting of SAEs to GSK ......................................................................... 73 
12.7. 
Appendix 7 - Genetic Research .......................................................................... 74 
12.8. 
Appendix 8: Definition of and Procedures for Documenting Medical 
Device Incidents................................................................................................... 77 
12.8.1. 
Definitions of a Medical Device Incident .................................................. 77 
12.8.1.1. 
Documenting Medical Device Incidents ........................................... 77 
12.9. 
Appendix 9: Protocol Changes .......................................................................... 79 
12.9.1. 
Amendment 1 － Summary of Changes and Rationale ..................... 79 
12.9.2. 
Amendment 2 － Summary of Changes and Rationale ..................... 82 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
9 
 
1. PROTOCOL SYNOPSIS FOR STUDY PHI201754 
 
Rationale 
This Phase III study will evaluate the efficacy and safety of daprodustat following a switch from 
erythropoietin-stimulating agents (ESA) in Japanese subjects with anemia associated with chronic 
kidney disease (CKD) on hemodialysis (HD) who are currently treated with ESA.  The primary 
objective is to demonstrate non-inferiority of daprodustat to darbepoetin alfa based on hemoglobin 
(Hgb) in the HD patient population included in this study. Study results will be used as pivotal study 
data for an NDA submitted for daprodustat for the treatment of renal anemia in Japan.  
 
Objective(s)/Endpoint(s) 
Objective 
Endpoint 
Primary (efficacy) 
• 
To demonstrate non-inferiority of 
daprodustat to darbepoetin alfa based on 
hemoglobin (Hgb) 
• 
Mean Hgb during the primary efficacy 
evaluation period (Weeks 40 to 52) 
Principal secondary (efficacy) 
• 
To demonstrate superiority of daprodustat 
to darbepoetin alfa in terms of 
achievement/maintenance of target Hgb 
• 
Number (%) of subjects with mean Hgb in the 
target range (10.0-12.0 g/dL) during the 
primary efficacy evaluation period (Weeks 40 
to 52) 
Other secondary (efficacy, PK) 
• 
To evaluate the appropriateness of the 
starting dose of daprodustat 
• 
Change from baseline in Hgb at Week 4 (Hgb 
increase rate) 
• 
Number (%) of subjects by Hgb change from 
baseline category at Week 4 
• 
To evaluate dose adjustment scheme of 
daprodustat 
• 
Distribution of the dose level 
• 
Duration of treatment interruption due to Hgb 
>13.0 g/dL 
• 
Frequency of dose adjustments 
• 
To evaluate the overall Hgb control of 
daprodustat using darbepoetin alfa as 
control 
• 
Hgb and change from baseline at each 
assessment visit 
• 
Number (%) of subjects who have a Hgb level 
within the target range (10.0–12.0 g/dL) at 
each assessment visit 
• 
Time (%) in Hgb target range (10.0–12.0 g/dL) 
during the primary efficacy evaluation period 
(Weeks 40 to 52) 
• 
Number (%) of subjects who have an Hgb 
level of less than 7.5 g/dL 
• 
Number (%) of subjects who have an Hgb 
increase of more than 2.0 g/dL over any 4 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
10 
 
Objective 
Endpoint 
weeks  
• 
Number (%) of subjects who have an Hgb 
level of more than 13.0 g/dL and number of 
episodes 
• 
To evaluate the PK of daprodustat 
• 
AUC and Cmax of plasma daprodustat 
Exploratory 
• 
To evaluate the effect of daprodustat on 
iron use using darbepoetin alfa as control 
• 
Dose of i.v. iron during the study period and 
the primary efficacy evaluation period 
(Weeks 40 to 52)  
• 
Number (%) of subjects who use i.v. iron 
during the study period and the primary 
efficacy evaluation period (Weeks 40 to 52) 
• 
To evaluate the effect of daprodustat on 
iron metabolism using darbepoetin alfa as 
control 
• 
Change from baseline in ferritin 
• 
Change from baseline in transferrin saturation 
(TSAT) 
• 
Changes from baseline in hepcidin 
• 
Change from baseline in serum iron 
• 
Change from baseline in total iron binding 
capacity (TIBC) 
Patient reported outcome 
• 
To evaluate the effect of daprodustat on 
health-related QoL (HR-QoL) using 
darbepoetin alfa as control 
SF-36 
• 
Changes from baseline in SF-36 HRQoL 
scores [Physical Component Summary (PCS), 
Mental Component Summary (MCS), and 8 
subscales] at Week 12, 28 and 52  
EQ-5D-5L/EQ-VAS 
• 
Change from baseline in EQ-5D-5L score at 
Week 12, 28 and 52 
• 
Change from baseline in EQ-VAS at Week 12, 
28 and 52 
Safety 
• 
To evaluate the safety and tolerability of 
daprodustat using darbepoetin alfa as 
control 
• 
Incidence and severity of AEs and SAEs, 
including AEs of special interest 
• 
Reasons for discontinuation of study 
medication 
• 
Laboratory tests, ECG, vital signs, and 
ophthalmology assessments 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
11 
 
Study Design 
This is a Phase III, double-blind (double-dummy), active-controlled, parallel-group, multi-center study 
designed to evaluate the efficacy (non-inferiority) and safety of daprodustat, when administered for 52 
weeks, compared to darbepoetin alfa in approximately 270 Japanese HD subjects with anemia associated 
with CKD who are currently treated with ESA.   
 
Approximately 270 eligible HD subjects will be randomized in a 1:1 ratio on Day 1to receive 
daprodustat or darbepoetin alfa (approximately 135 subjects per group).  
 
This study consists of a 2~4 week screening phase, a 52 week treatment phase [including the primary 
efficacy evaluation period (Weeks 40 to 52)], and a 2-week follow-up phase following the treatment 
phase.  The study design is shown below.  
 
 
 
 
 
 
 
 
 
 
Screening phase 
(2~4 weeks) 
 
Treatment phase (52 weeks) 
 
Follow-up phase 
(2 weeks) 
 
 
Primary efficacy 
evaluation period 
 
 
 
 
 
 
 
 
 
 
 (HD)／ 
 
Daprodustat group (N=135) 
 
 
 
 
hemodiafiltration 
(HDF) 
 
 
 
 
 
 
patients 
 
Darbepoetin alfa group (N=135) 
 
 
 
 
 
 
 
 
 
 
Week -4~-2       Day 1            Week 40       Week 52     Week 54 
 
 
Method of Administration of Study Medication in Each Treatment Group 
In each treatment group, study medication will be administered as follows:  
• 
Daprodustat group: Subjects will receive oral daprodustat once daily and intravenous darbepoetin 
alfa matching placebo once weekly. Daprodustat will be started at a dose of 4 mg once daily 
(starting dose) on Day 1. From Week 4 onwards, dose adjustments will be made within the dose 
range of 1-24 mg every 4 weeks according to the prespecified dose adjustment algorithm to 
achieve and/or maintain Hgb within the target range (10.0-12.0 g/dL). 
• 
Darbepoetin alfa group: Subjects will receive oral daprodustat matching placebo once daily and 
intravenous darbepoetin alfa once weekly. Prior ESA therapy will be replaced with intravenous 
treatment with darbepoetin alfa at the corresponding dose once weekly according to the 
prespecified dose conversion. Subsequently, dose adjustments will be made within the dose 
range of 10-60 µg once every 2 weeks according to the prespecified dose adjustment algorithm to 
achieve and/or maintain Hgb within the target range (10.0-12.0 g/dL). 
 
Analysis 
Assuming a non-inferiority margin of -1.0 g/dL, a treatment difference of 0.0 g/dL, and a standard 
deviation of 1.5 g/dL for mean Hgb during the primary efficacy evaluation period in HD subjects, 
two-sample t-test has at least 99% power at a one-sided significance level of 2.5% (i.e. two-sided 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
12 
 
significance level of 5%) with a sample size of 100 subjects per group. Assuming a dropout rate of 
approximately 25%, aproximately 135 subjects will be randomized to each group.  
 
The primary endpoint, which is the mean Hgb during the primary efficacy evaluation period, will be 
analyzed to demonstrate the non-inferiority of daprodustat to darbepoetin alfa in HD subjects.  
A mixed model for repeated measurements (MMRM) will be used to estimate the mean Hgb during 
the primary efficacy evaluation period and its 95% CI by treatment groups. As a preliminary 
assessment, it will be confirmed if the lower and upper limit of 95% CI for mean Hgb during the 
primary efficacy evaluation period in daprodustat group would lie fully within target range (10.0-
12.0 g/dL) at first. In addition, the point estimate and 95% CI for the treatment difference (daprodustat 
- darbepoetin alfa) in mean Hgb during the primary efficacy evaluation period will be estimated. Non-
inferiority will be established if the lower limit of the 95% CI is greater than -1.0 g/dL. Even if the 
95% CI for the difference is completely negative (i.e. lies fully within the range -0.75 to <0 g/dL) non-
inferiority would still be concluded on condition that the mean Hgb estimate in the daprodustat group 
is within the target range. 
The primary efficacy population will be the Intent-to-Treat (ITT) Population, and the analysis will be 
repeated in the modified ITT (mITT) and Per-Protocol (PP) Population to evaluate the robustness of 
the conclusion.  Following sensitivity analyses will be conducted to assess robustness of study result.  
• 
If there are Hgb considered to be impacted by blood transfusion or marketed rhEPO/ESAs, 
sensitivity analysis excluding the Hgb values from the analyses of primary endpoint will be 
conducted. 
• 
Analysis of covariance (ANCOVA) will be conducted as sensitivity analysis to MMRM. This 
model includes treatment group and baseline Hgb. The analysis population will be mITT 
population and the similar analysis will be repeated in the PP population. 
• 
A tipping point analysis based on multiple imputation will be conducted as sensitivity analysis to 
missing data assumption. This analysis explores a point where non-inferiority is not confirmed 
(tipping point) by changing assumption to missing data and repeating imputation. The analysis 
population will be ITT population and the similar analysis will be repeated in the mITT and PP 
population. 
Further details of sensitivity analyses will be provided in the Reporting and Analysis Plan (RAP). 
 
The principal secondary endpoint, which is the proportion of subjects whose mean Hgb during the 
primary efficacy evaluation period is within the target range, will be analyzed to demonstrate the 
superiority of daprodustat to darbepoetin alfa in HD subjects.  
In the mITT Population, a logistic regression model including treatment group and baseline Hgb as 
covariates will be used to estimate the point estimate and 95% CI for the odds ratio (daprodustat / 
darbepoetin alfa). This analysis will be performed to demonstrate the superiority at a two-sided 
significance level of 5%, conditional on the primary endpoint achieving noninferiority. Superiority 
will be established if the lower limit of the 95% CI for the odds ratio is greater than 1.0. 
 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
13 
 
2. INTRODUCTION 
Daprodustat is a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) that stimulates 
erythropoiesis in the same manner as innate response to hypoxia and is currently being developed as a 
new treatment for renal anemia.  
 
2.1. 
Study Rationale  
This is a Phase III study to evaluate the efficacy and safety of daprodustat following a switch from 
ESA in Japanese HD subjects with renal anemia who are currently treated with ESA. The primary 
objective is to demonstrate non-inferiority of daprodustat to darbepoetin alfa based on Hgb in the HD 
patient population included in this study. Study results will be used as pivotal study data for an NDA 
submitted for daprodustat for the treatment of renal anemia in Japan.  
 
2.2. 
Background 
Renal anemia is diagnosed in many patients with CKD, and the prevalence of renal anemia increases 
with progression of CKD [Akizawa, 2011]. Causes of anemia in CKD patients include absolute or 
relative deficiency of erythropoietin (EPO), shortened erythrocyte survival, and reduced iron 
availability. Anemia is further exacerbated by chronic blood loss associated with hemodialysis 
procedure, infection, and functional hemolysis [Japanese Society for Dialysis Therapy, 2016].  
 
Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor that is currently being 
developed as a treatment for renal anemia. Data in Japanese patients have been collected from a 
Japanese Phase II 4-week treatment study in Japanese hemodialysis (HD) subjects (PHI116099: 97 
Japanese subjects), an international multi-center Late Phase II 24-week treatment study in HD subjects 
(PHI113633: including 24 Japanese subjects), and an international multi-center Late Phase II 24-week 
treatment study in Non-dialysis subjects (PHI113747: including 42 Japanese subjects). In these 
clinical studies, daprodustat increased endogenous EPO, reduced hepcidin, and increased Hgb in HD 
and ND subjects including Japanese subjects. In addition, daprodustat increased Hgb at lower blood 
EPO concentrations than existing ESAs.  
 
Summaries of findings from both clinical and non-clinical studies conducted with daprodustat can be 
found in the daprodustat Investigator’s Brochure (IB) and IB supplement(s) (if applicable).  
A benefit: risk assessment, including risk mitigation strategies, is outlined in Section 4.6. 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
14 
 
3. OBJECTIVES AND ENDPOINTS 
Objective 
Endpoint 
Primary (efficacy) 
• 
To demonstrate non-inferiority of 
daprodustat to darbepoetin alfa based on 
hemoglobin (Hgb) 
• 
Mean Hgb during the primary efficacy 
evaluation period (Weeks 40 to 52) 
Principal secondary (efficacy) 
• 
To demonstrate superiority of daprodustat 
to darbepoetin alfa in terms of 
achievement/maintenance of target Hgb 
• 
Number (%) of subjects with mean Hgb in the 
target range (10.0-12.0 g/dL) during the 
primary efficacy evaluation period (Weeks 40 
to 52) 
Other secondary (efficacy, PK) 
• 
To evaluate the appropriateness of the 
starting dose of daprodustat 
• 
Change from baseline in Hgb at Week 4 (Hgb 
increase rate) 
• 
Number (%) of subjects by Hgb change from 
baseline category at Week 4 
• 
To evaluate dose adjustment scheme of 
daprodustat 
• 
Distribution of the dose level 
• 
Duration of treatment interruption due to Hgb 
>13 g/dL 
• 
Frequency of dose adjustments 
• 
To evaluate the overall Hgb control of 
daprodustat using darbepoetin alfa as 
control 
• 
Hgb and change from baseline at each 
assessment visit 
• 
Number (%) of subjects who have a Hgb level 
within the target range (10.0–12.0 g/dL) at 
each assessment visit 
• 
Time (%) in Hgb target range (10.0–12.0 g/dL) 
during the primary efficacy evaluation period 
(Weeks 40 to 52) 
• 
Number (%) of subjects who have an Hgb 
level of less than 7.5 g/dL 
• 
Number (%) of subjects who have an Hgb 
increase of more than 2 g/dL over any 4 weeks  
• 
Number (%) of subjects who have an Hgb 
level of more than 13.0 g/dL and number of 
episodes 
• 
To evaluate the PK of daprodustat 
• 
AUC and Cmax of plasma daprodustat 
Exploratory 
• 
To evaluate the effect of daprodustat on 
iron use using darbepoetin alfa as control 
• 
Dose of i.v. iron during the study period and 
the primary efficacy evaluation period 
(Weeks 40 to 52)  
• 
Number (%) of subjects who use i.v. iron 
during the study period and the primary 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
15 
 
Objective 
Endpoint 
efficacy evaluation period (Weeks 40 to 52) 
• 
To evaluate the effect of daprodustat on 
iron metabolism using darbepoetin alfa as 
control 
• 
Change from baseline in ferritin 
• 
Change from baseline in transferrin saturation 
(TSAT) 
• 
Changes from baseline in hepcidin 
• 
Change from baseline in serum iron 
• 
Change from baseline in total iron binding 
capacity (TIBC) 
Patient reported outcome 
• 
To evaluate the effect of daprodustat on 
health-related QoL (HR-QoL) using 
darbepoetin alfa as control 
SF-36 
• 
Changes from baseline in SF-36 HR-QoL 
scores [Physical Component Summary (PCS), 
Mental Component Summary (MCS), and 8 
subscales] at Week 12, 28 and 52  
EQ-5D-5L/ EQ-VAS 
• 
Change from baseline in EQ-5D-5L score at 
Week 12, 28 and 52 
• 
Change from baseline in EQ-VAS at Week 12, 
28 and 52  
Safety 
• 
To evaluate the safety and tolerability of 
daprodustat using darbepoetin alfa as 
control 
• 
Incidence and severity of AEs and SAEs, 
including AEs of special interest 
• 
Reasons for discontinuation of study 
medication 
• 
Laboratory tests, ECG, vital signs, and 
ophthalmology assessments 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
16 
 
4. STUDY DESIGN 
4.1. 
Overall Design  
This is a Phase III, double-blind (double-dummy), active-controlled, parallel-group, multi-center study 
designed to evaluate the efficacy (non-inferiority) and safety of daprodustat, when administered for 52 
weeks, compared to darbepoetin alfa in approximately 270 Japanese HD subjects with anemia 
associated with CKD who are currently treated with ESA.   
 
Two hundreds seventy (270) eligible HD subjects will be randomized in a 1:1 ratio to receive 
daprodustat or darbepoetin alfa (135 subjects per group).  
 
This study consists of a 2~4 week screening phase, a 52 week treatment phase [including the primary 
efficacy evaluation period (Weeks 40 to 52)], and a 2-week follow-up phase following the treatment 
phase. The study design is shown in Figure 1. 
 
 
 
 
 
 
 
 
 
 
Screening phase 
(2~4 weeks) 
 
Treatment phase (52 weeks) 
 
Follow-up phase 
(2 weeks) 
 
 
Primary efficacy 
evaluation period 
 
 
 
 
 
 
 
 
 
 
 (HD)／ 
 
Daprodustat group (N=135) 
 
 
 
 
hemodiafiltration 
(HDF) 
 
 
 
 
 
 
patients 
 
Darbepoetin alfa group (N=135) 
 
 
 
 
 
 
 
 
 
 
Week -4~-2       Day 1            Week 40       Week 52     Week 54 
Figure 1 Study Design 
 
 
4.2. 
Treatment Groups and Study Periods 
Details for each study period and treatments are described below. In this study, a point-of-care Hgb 
analyzer (HemoCue®) will consistently be utilized for confirmation of subjects’ eligibility, 
withdrawal criteria and dose adjustments of study medication. 
 
Screening phase 
Subjects who have provided informed consent and meet all of the eligibility criteria at screening 
(Week -4~-2) (Sections 5.1 and 5.2) will be provisionally enrolled in the study. Subjects who have 
used oral iron since before the start of the study must remain on the same regimen throughout the 
screening phase (intravenous iron will not be allowed). Subjects will also continue to use ESA 
throughout the screening phase. The regimen of ESA therapy should remain unchanged throughout 
the screening phase. 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
17 
 
Treatment phase 
Subjects who meet all of the eligibility criteria at the start of the treatment phase (Day 1) will be 
randomized in a 1:1 ratio to receive daprodustat or darbepoetin alfa and enrolled in the study. Subjects 
will be ESA users and will switch their ESA therapy to darprodustat at Day 1 so that the 
randomization date (Day 1) should coincide, as closely as possible, with the date of next scheduled 
ESA administration. In accordance with the randomization instructions, subjects randomized to the 
daprodustat group will receive daprodustat and darbepoetin alfa matching placebo for 52 weeks. 
Subjects randomized to the darbepoetin alfa group will receive daprodustat matching placebo and 
darbepoetin alfa for 52 weeks. Daprodustat will be orally administered once daily, and darbepoetin 
alfa will be intravenously administered once weekly. In both groups, dose adjustments for study 
medication during the treatment phase will be made according to the administration schedule specified 
in Section 6.4 to achieve and/or maintain Hgb within the target range (10.0-12.0 g/dL). In addition, 
supplemental iron therapy will be administered according to the standard initiation criteria as 
described in Section 6.12. It should be noted that intravenous iron or dose change for oral iron will not 
be allowed from Day 1 to Week 4.  
 
Follow-up phase 
Subjects will visit the site for follow-up assessments and observations 2 weeks after the 
completion/discontinuation of study treatment. During the follow-up phase, treatment of renal anemia 
will be allowed as necessary at the discretion of the investigator (or subinvestigator).  
 
4.3. 
Study Subjects and Number of Subjects 
A total of 270 subjects will be randomized (daprodustat group: 135 subjects, darbepoetin alfa group: 
135 subjects). Assuming a dropout rate of 30% during the screening phase, approximately 386 
subjects need to be screened. Assuming a dropout rate of 25% after the start of study treatment, a total 
of 202 subjects are expected to complete the 52-week treatment.  
 
Table 1    Target Number of Subjects 
Screened 
386 
Randomized/enrolled 
270 
Completed 52-week treatment 
202 
 
 
4.4. 
Rationale for Study Design 
Objectives and evaluations 
This is a Phase III study to evaluate the efficacy and safety of daprodustat in Japanese HD subjects 
with renal anemia who are currently treated with ESA. The study is designed as an active-controlled, 
parallel-group comparative study which will be conducted under double blind to meet the primary 
objective, that is, to demonstrate non-inferiority of daprodustat to the existing drug based on Hgb in 
HD subjects. The target Hgb range was set for study treatment in line with the Guidelines for Renal 
Anemia in Chronic Kidney Disease issued by the Japanese Society for Dialysis Therapy in 2015 [The 
Japanese Society for Dialysis Therapy, 2016] to demonstrate that treatment with daprodustat can 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
18 
 
result in achievement and/or maintenance of target Hgb in HD subjects, and evaluate the 
appropriateness of the starting dose of daprodustat.  
 
Control 
Darbepoetin alfa, which has been widely used in Japanese patients with renal anemia, primarily HD 
patients, since its approval in Japan in 2007, was selected as control.  
 
 
4.5. 
Rationale for Dose Levels 
Starting dose and dose adjustments of daprodustat 
The starting dose (4 mg) and the dose adjustment method (maintenance dose range: 1-24 mg) for 
daprodustat are described in Section 6.4.  
The starting dose and the dose adjustment algorithm selected for Japanese HD subjects in the present 
study are based on the results from a review of the longitudinal model constructed using Hgb data 
from six Japanese or overseas Phase II studies (PHI112844, PHI116581, PHI116582, PHI113633, 
PHI113747, and PHI116099) as well as the results from clinical studies. The data set used in the 
model analyses was based on the data of daprodustat administered in a wide dose range (0-25 mg) and 
included a Japanese Phase II 4-week treatment study (PHI116099) and international multi-center late 
Phase II 24-week treatment studies (PHI113633 and PHI113747) in which subjects in Japan 
participated. 
 
Starting dose 
Simulations using a longitudinal model as well as clinical data for HD subjects suggested that Hgb 
levels observed with prior ESA therapy is maintained for 4 weeks after a switch from prior ESA to 
study medication, with no rapid increase greater than 2 g/dL, at the dose level of 4 mg in ESA user 
subjects. Covariate analyses identified baseline Hgb, body weight, and dose level of prior ESA as 
major factors affecting Hgb. However, Hgb was more greatly affected by inter-subject differences in 
drug response to daprodustat than these factors.  
Taken together, 4 mg may be an appropriate starting dose of daprodustat for the majority of ESA users.  
 
Maintenance dose range and dose adjustment algorithm 
Simulation results using the longitudinal model showed that drug response to daprodustat regarding 
Hg greatly varied among subjects, indicating that the dose range from 1 to 24 mg may be necessary to 
achieve and maintain target Hgb. Accordingly, a total of 8 dose levels (1, 2, 4, 6, 8, 12, 18, and 24 mg) 
were selected as the maintenance doses, with 4 mg intended for subjects with a standard drug response.  
The dose adjustment algorithm was defined so that target Hgb (10.0-12.0 g/dL) set for the present 
study according to the Guidelines for Renal Anemia [The Japanese Society for Dialysis Therapy, 
2016] can be maintained. Given a difference of 1.0 g/dL between the the upper limit of Hgb target 
range (12.0 g/dL) and ESA dose interruption criteria value (13.0 g/dL), the dose of daprodustat will be 
reduced to the one step lower dose level when Hgb increases into the range of 12.0−13.0 g/dL. Since it 
is well known that an Hgb increase of 0.5 g/dL or less per week is appropriate to prevent adverse 
reactions, the dose level will be reduced by one step when Hgb increases by more than 2 g/dL over 4 
weeks [KDIGO, 2012]. For subjects whose anemia needs to be corrected (≥7.5 g/dL and <10.0 g/dL), 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
19 
 
the dose level will be maintained while the Hgb increase per 4 weeks is 0.5-2 g/dL, and the dose level 
will be increased by one step when the Hgb increase per 4 weeks is less than 0.5 g/dL.  
 
Starting dose and dose adjustments of control (darbepoetin alfa) 
The starting doses and dose adjustment algorithm for darbepoetin alfa are described in Section 6.4.  
The starting doses of darbepoetin alfa for subjects currently treated with epoetin were selected based 
on the prescribing information in Japan. For subjects on epoetin beta pegol, given that no 
recommended starting doses of darbepoetin alfa when switched from epoetin beta pegol approved in 
Japan is available, switchig will be performed in the epoetin beta pegol-to-darbepoetin alfa dose ratio 
of 5:6 at the middle dose level of darbepoetin alfa according to the overseas prescribing information 
[MIRCERA. Product information in Europe, 2012]. At the other dose levels, dose conversion will be 
performed within the approved dose levels and in a dose ratio close to 5:6. 
The dose adjustment algorithm for darbepoetin alfa was determined based on the product information 
and previous Japanese clinical studies in accordance with the Guideline for Renal Anemia in Chronic 
Kidney Disease [Japanese Association for Dialysis Therapy, 2016]. 
 
4.6. 
Benefit: Risk Assessment 
Summaries of findings from clinical and nonclinical studies of daprodustat can be found in the IB and 
the IB supplements. The risk assessment and risk minimization strategies for the present study are 
outlined in the following sections:  
 
4.6.1. 
Risk Assessment 
The potential risks of clinical significance including AEs of special interest (Section 7.4.2) and the 
mitigation strategies for this protocol taking into account the results of completed clinical and 
nonclinical studies of daprodustat, are outlined in Section 12.2. Appendix 2. 
 
4.6.2. 
Benefit Assessment  
Study PHI201754 is a Phase 3 study in Japanese HD subjects with renal anemia who are treated with 
ESA. Previous clinical studies of daprodustat, administered for up to 24 weeks in ND or HD subjects 
have demonstrated clinical efficacy (increase in and/or maintenance of Hgb) with blood EPO 
concentrations increased within the normal physiologic range in CKD subjects. Data obtained in 
Study PHI201754 will generate safety and efficacy data in Japanese HD subjects with renal anemia 
who are treated with ESA, for a 52-week treatment period. Study participants who will receive 
daprodustat, may benefit from the expected clinical efficacy.  
Daprodustat, may have important advantages over existing ESAs. Daprodustat, which is orally 
administered and requires no cold chain management unlike ESAs, is more convenient to patients and 
health care provider. Daprodustat is shown to increase Hgb at lower EPO concentrations than ESAs. 
Since increased exposure to EPO following administration of ESAs may be associated with an 
increased cardiovascular risk [Szczech, 2008], daprodustat may increase Hgb without increasing the 
cardiovascular risk.  
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
20 
 
4.6.3. 
Overall Benefit: Risk Conclusion 
Daprodustat is shown to have a positive benefit-risk balance based on the following findings: in 
studies of daprodustat administered for up to 24 weeks, treatment with daprodustat resulted in 
achievement of target Hgb, and no adverse events have been identified as related to treatment with 
daprodustat.  
 
This protocol employs precautions to mitigate known and potential risks to enrolled subjects (see 
Section 12.2. Appendix 2). Given these precautions, as well as the potential benefit that daprodustat 
holds for the treatment of renal anemia compared with the current standard treatment, the overall 
benefit risk balance is considered to be positive.  
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
21 
 
5. SUBJECT SELECTION AND WITHDRAWAL CRITERIA 
Specific information regarding warnings, precautions, contraindications, adverse events, and other 
pertinent information on the GSK investigational product or other study treatment that may impact 
subject eligibility is provided in the IB/IB supplement(s) and/or other pertinent documents. 
 
Deviations from inclusion/exclusion criteria are not allowed because they can potentially jeopardize 
the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to 
the criteria as specified in the protocol is essential. 
 
5.1. 
Inclusion Criteria 
Subjects eligible for enrolment in the study must meet all of the inclusion criteria. 
Note: Verification at both provisional enrolment (screening) and official enrolment (Day 1) is required, 
unless otherwise specified.  
 
1. 
Age (informed consent): ≥20 years of age 
2. 
Dialysis: On hemodialysis (HD) or hemodiafiltration (HDF) given three times weekly for at least 
12 weeks prior to screening 
3. 
ESAs: Use of one and the same ESA for at least 10 weeks prior to screening 
4. 
ESA dose: Darbepoetin alfa 10 - 60 µg per week, epoetin (including biosimilars) ≤9000 IU per 
week, or epoetin beta pegol up to 250 μg per 4 weeks 
Note: ESA dose must be greater than the minimum ESA dose if Hgb >12 g/dL to 12.5 g/dL 
(Minimum ESA dose: epoetins (including biosimilars): 1500 units (U) per week; darbepoetin 
alfa: 10 μg per week; epoetin beta pegol: 25 μg per evey 4 weeks) 
5. 
Hemoglobin (Hgb): ≥9.5 g/dL and ≤12.5 g/dL. Determined at the site using an Hgb analyzer 
(HemoCue®)  
6. 
Iron parameters: Ferritin >100 ng/mL or TSAT >20% (screening verification only) 
7. 
Gender (screening verification only): Female or male 
Females: Not pregnant [demonstrated to be negative for human chorionic gonadotropin (hCG) in 
serum], not breast-feeding, and meet at least one of the following:  
1) 
Females of non-childbearing potential are defined as follows:  
• 
Pre-menopausal with at least one of the following and no plans to utilise assisted 
reproductive techniques (e.g., in vitro fertilisation or donor embryo transfer): 
• 
History of bilateral tubal ligation or salpingectomy 
• 
History of hysteroscopic tubal occlusion and postoperatively documented bilateral 
tubal obstruction  
• 
History of hysterectomy 
• 
History of bilateral oophorectomy 
• 
Postmenopausal defined as A) females 60 years of age or older or B) In females < 60 years 
of age, 12 months of spontaneous amenorrhea [in questionable cases a blood sample with 
postmenopausal follicle stimulating hormone (FSH) and estradiol concentrations is 
confirmatory (see separately specified reference ranges)]. Females on HRT whose 
menopausal status is in doubt will be required to use one of the most effective contraception 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
22 
 
methods if they wish to continue their HRT during the study. Otherwise they must 
discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.  
2) 
Females of childbearing potential must agree to comply with one of the contraception 
methods listed as requirements in “GSK Listing of Most Effective Contraceptive Methods for 
Females of Childbearing Potential (Section 12.3. Appendix 3: Modified List of Highly Effective 
Methods for Avoiding Pregnancy in Females of reproductive potential)” from at least 28 days 
prior to the first dose of study medication until the completion of the follow-up visit. 
8. 
Informed consent: Written informed consent, including adherence to the requirements and 
conditions specified in the consent form and the protocol, must be obtained from each subject as 
specified in Section10.2...  
 
5.2. 
Exclusion Criteria 
Subjects meeting any of the following criteria must not be enrolled in the study.  
Note: Verification at both provisional enrolment (screening) and official enrolment (Day 1) is required, 
unless otherwise specified. 
 
Chronic kidney disease (CKD)-related criteria  
1. 
Kidney transplant: Planned living-related kidney transplant during the study 
 
Anemia-related criteria 
2. 
Aplasia: History of bone-marrow hypoplasia or pure red cell aplasia 
3. 
Other causes of anemia: pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic 
syndromes 
4. 
Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal 
ulcer disease OR clinically significant GI bleeding within 10 weeks prior to screening or during a 
period from screening to Day 1. 
 
Cardiovascular disease-related criteria 
5. 
Myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack: Diagnosed 
within 10 weeks prior to screening or during a period from screening to Day 1.  
6. 
Heart failure: Chronic Class IV heart failure, as defined by the New York Heart Association 
(NYHA) functional classification system 
7. 
Corrected QT (QTc) Interval (screening verification only): QTc >500 msec; or QTc >530 msec 
in subjects with bundle branch block  
Note: QT interval corrected using the Bazett’s formula (QTcB) will be used, and ECG can be 
mechanically or manually read.  
 
Other disease-related criteria 
8. 
Liver disease (if any of the following occurs):  
• 
(Screening verification only): Alanine transaminase (ALT) >2×upper limit of normal (ULN) 
• 
(Screening verification only): Bilirubin >1.5×ULN (isolated bilirubin >1.5×ULN is 
acceptable if bilirubin is fractionated and direct bilirubin is <35%) 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
23 
 
• 
Current unstable active liver or biliary disease (generally defined by the onset of ascites, 
encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent 
jaundice, or cirrhosis) 
Note: Stable liver disease (including asymptomatic gallstones, chronic hepatitis B/C, or 
Gilbert’s syndrome) is acceptable if the subject otherwise meets entry criteria.. 
9. 
Malignancy: History of malignancy within 2 years prior to screening, currently receiving 
treatment for cancer, or complex kidney cyst >3 cm (II F, III or IV based on the Bosniak 
classification) 
Note: The only exception is localized squamous cell or basal cell carcinoma of the skin that has 
been definitively treated ≥ 10 weeks before screening. 
 
Concomitant medication and other study treatment-related criteria 
10. Iron: Planned use of intravenous iron during the screening phase or during a period from Day 1 
to Week 4 
Note: Oral iron is acceptable. However, the same dose regimen must be used throughout the 
screening phase and from Day 1 to Week 4. Antihyperphosphatemic agents containing iron (e.g., 
ferric citrate hydrate) are also acceptable only if used for at least 12 weeks prior to screening. 
However, they must be continued throughout the screening phase from Day 1 to Week 4.  
11. Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity 
to excipients in the investigational product (see the daprodustat IB or the Prescribing Information 
of the darbepoetin alfa) 
12. Drugs and supplements: Use or planned use of any prescription or non-prescription drugs or 
dietary supplements that are prohibited during the study period [prohibited medications: strong 
inducers and inhibitor of Cytochrome P450 (CYP) 2C8, see Section 6.11.2] 
13. Prior investigational product exposure: Use of an investigational agent within 30 days or five half 
lives of the investigational agent (whichever is longer) 
14. Prior treatment with daprodustat: Any prior treatment with daprodustat for a treatment duration 
of >30 days 
 
General health-related criteria 
15. Other conditions: Any other condition, clinical or laboratory abnormality, or examination finding 
that the investigator (or subinvestigator) considers would put the subject at unacceptable risk, 
which may affect study compliance or prevent understanding of the aims or investigational 
procedures or possible consequences of the study 
 
5.3. 
Screening Failures 
Screen failures are defined as subjects who consent to participate in the clinical trial, but are not 
subsequently randomized in the study. A minimum set of information is required from screen failure 
subjects including Demography, Screen Failure details, Eligibility Criteria, and SAEs in order to 
report screen failures in a reliable manner, satisfy the requirements for publication defined by the 
Consolidated Standards of Reporting Trials (CONSORT), and respond to requests of the regulatory 
authorities.  

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
24 
 
Subjects that fail screening are eligible to be rescreened up to 3 times as soon as the investigator 
assesses they may meet study entry criteria. For re-screening subjects, ophthalmology exam to be 
performed at re-screening could be replaced with the results of the most recent ophthalmology 
screening, on the investigator’s (or subinvestigator’s) discretion (See Table 10). 
 
5.4. 
Permanent discontinuation of study treatment and study withdrawal  
If subjects meet one of the following criteria, study treatment should be permanently discontinued and 
subjects will be withdrawn from the study. The withdrawal reason should be recorded.  
 
• 
Hgb <7.5 g/dL 
Note: HemoCue Hgb values will be employed. If an initial Hgb value meets the Hgb stopping 
criteria, measurement will be repeated at the same study visit (using the same sample) to 
calculate the average. If the average meets the Hgb stopping criteria, study treatment will be 
discontinued.  
• 
Kidney transplant 
• 
Subject becomes pregnant or intends to become pregnant during the study. 
• 
Diagnosis of new or recurrent cancer 
• 
Liver chemistry abnormalities exceeding the threshold criteria (see Section5.4.1.) 
• 
Need for chronic (more than 14 days) use of prohibited medication (strong inhibitors/ inducers of 
CYP2C8 meet this criteria) 
• 
When the investigator (or subinvestigator) considers necessary to withdraw the subject from the 
study for other reasons  
 
Subjects who meet any of the withdrawal criteria or are withdrawn for other reasons during the 
treatment phase should be assessed at withdrawal visit after study treatment is discontinued, and will 
then enter the follow-up phase.  
Should a subject fail to attend a required study visit, the investigator (or subinvestigator) should take 
the following measures:  
• 
The investigator (or subinvestigator) or designee should attempt to contact the subject and re-
schedule the missed visit as soon as possible.  
• 
The investigator (or subinvestigator) should counsel the subject on the importance of maintaining 
the assigned visit schedule and determine whether the subject is willing to continue his/her 
participation in the study and/or whether the subject should remain in the study.  
• 
The investigator (or subinvestigator) or designee should make every effort to regain contact with 
a subject who is deemed “Lost to Follow-up”. All efforts to contact the subject should be 
documented in the subject’s clinical charts.  
• 
Should the subject continue to be unreachable, then and only then will he/she be considered 
“Lost to Follow-up.” 
 
A subject may withdraw from the study at any time at his/her own request. The investigator (or 
subinvestigator) may withdraw a subject from the study at any time for safety or compliance reasons 
or study conduct considerations. If a subject withdraws from the study, he/she may request destruction 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
25 
 
of any clinical samples taken, and the investigator (or subinvestigator) must document this in the site 
study records. 
 
5.4.1. 
Liver Chemistry Stopping Criteria 
Liver chemistry stopping and increased monitoring criteria have been designed to assure subject 
safety and evaluate liver event etiology [in alignment with the Food and Drug Administration (FDA) 
premarketing clinical liver safety guidance]. 
 
Liver Chemistry Stopping and Increased Monitoring Algorithm 
Continue Study Treatment 
Discontinue Study Treatment 
Plus 
Bilirubin≥2x
ULN (>35% 
direct) or plus
INR>1.5, if 
measured*
Possible  
Hy’s Law
ALT≥3xULN
ALT
≥8xULN
Plus
Symptoms of 
liver injury
or 
hypersensitivity
No
Yes
Yes
Yes
No
No
No
See algorithm 
for continued 
therapy with 
increased liver 
chemistry 
monitoring
Yes
*INR value not applicable to subjects on anticoagulants 
ALT 
≥3xULN 
but 
<8xULN
Yes
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*
 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
26 
 
Liver Chemistry Increased Monitoring Algorithm with Continued Therapy for ALT ≥3xULN 
but <8xULN 
Continue Study Treatment   and   Monitor Liver Chemistry
Discontinue Study Treatment 
ALT≥5xULN 
but <8xULN
+ bili <2xULN +
no symptoms
No
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Yes
ALT ≥3xULN 
but <5xULN
+ bili <2xULN  +
no symptoms
Able to 
monitor  
weekly 
for  ≥2 
weeks
Persists for 
≥2 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
No
No
Able to 
monitor  
weekly 
for  ≥4 
weeks
Persists for 
≥4 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
Yes
ALT ≥5xULN 
ALT <5xULN 
Yes
Yes
*INR value not applicable to subjects on anticoagulants 
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*
 
 
Liver Safety Required Actions and Follow up Assessments Section can be found in Section 12.5. 
Appendix 5 
 
5.4.1.1. 
Study Treatment Restart or Rechallenge 
Study treatment restart or rechallenge after liver chemistry stopping criteria are met by any subject 
participating in this study is not allowed. 
 
 
5.5. 
Subject and Study Completion 
A completed subject is one who has completed all periods of the study including the follow-up visit. 
The study will be completed with the last subject’s last study visit.  
 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
27 
 
6. STUDY TREATMENTS 
6.1. 
Investigational Product and Other Study Treatment 
The term ‘study treatment’ is used throughout the protocol to describe any products received by the 
subject as per the protocol design. Accordingly, ‘study treatment’ sometimes refers to each product 
and sometimes refers to multiple products.  
 
Daprodustat (study drug) 
The study drug daprodustat will be supplied as fast-release film coated tablets for oral administration 
containing 1 mg, 2 mg, 4 mg, or 6 mg of daprodustat (Table 2). The daprodustat matching placebo 
will be supplied as film coated tablets, it visually matches the daprodustat tablets, for oral 
administration containing no daprodustat (Table 2). There are two sizes each for the daprodustat and 
placebo tablets. 
 
Table 2   Description of daprodustat and placebo tablets 
Daprodustat or placebo tablets 
Description 
Daprodustat (small) 
(1 mg, 2 mg, and 4 mg tablets 
7.0 mm round, standard biconvex, white film coated tablets containing 
1 mg, 2 mg, or 4 mg of daprodustat as active ingredient 
Daprodustat (large) 
(6 mg tablets) 
9.0 mm round, standard biconvex, white film coated tablets containing 
6 mg of daprodustat as active ingredient 
Placebo (small) 
7.0 mm round, standard biconvex, white film coated tablets containing no 
daprodustat 
Placebo (large) 
9.0 mm round, standard biconvex, white film coated tablets containing no 
daprodustat 
 
Daprodustat and placebo tablets are packed by strength or by size in high density polyethylene bottles, 
with 35 tablets per bottle. Subjects are to take one to four tablets (Table 3) with water once daily 
according to the dose level indicated at each study visit. Subjects can take daprodustat tablets without 
regard to food or hemodialysis. The administration schedule (starting dose and dose adjustment) 
described in Section 6.4.1 should be followed.  
 
Table 3    Dose levels of daprodustat and number of tablets taken 
Dose level of 
daprodustat 
(once daily) 
1 mg 
2 mg 
4 mg 
6 mg 
8 mg 
12 mg 
18 mg 
24 mg 
Number of 
daprodustat 
tablets taken 
1 mg 
tablet 
×1 
2 mg 
tablet 
×1 
4 mg 
tablet 
×1 
6 mg 
tablet 
×1 
4 mg 
tablet 
×2 
6 mg 
tablet 
×2 
6 mg 
tablet 
×3 
6 mg 
tablet 
×4 
 
Subjects should be instructed to bring daprodustat/placebo tablets with bottles at each study visit, and 
all unused daprodustat tablets will be collected from subjects at every 4 week’s study visit. 
 
Darbepoetin Alfa (Control) 
GSK will provide the control drug of darbepoetin alfa (NESP Injection) and its matching placebo. 
Darbepoetin alfa is provided as 0.5 mL plastic prefilled syringes (PFS) for IV injection each 
containing 10, 15, 20, 30, 40 or 60 µg of darbepoetin alfa in a clear and colorless solution. 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
28 
 
Darbepoetin alfa placebo is provided as 0.5 mL plastic prefilled syringes (PFS) for IV injection 
containing no darbepoetin alfa in a clear and colorless solution. 
Subjects will receive intravenous darbepoetin alfa or placebo once weekly at the study site (Table 4) 
according to the dosing schedule (including starting doses and dose adjustment algorithm) provided in 
Section 6.4.2. 
 
Table 4    Dose levels of darbepoetin alfa and injection frequency 
Dose level of darbepoetin alfa   
(once weekly) 
10 µg 
15 µg 
20 µg 
30 µg 
40 µg 
60 µg 
Number of IV injection of 
darbepoetin alfa 
10 µg IV 
×1 
15 µg IV 
×1 
20 µg IV
×1 
30 µg IV 
×1 
40 µg IV 
×1 
60 µg IV 
×1 
 
 
6.2. 
Medical Device 
The darbepoetin alfa (Brand name : NESP Injection) marketed with the device (kit formulation which 
was filled liquid medication in plastic prefilled syringes) provided for use in this study. 
Instructions for medical device are described in the Prescribing Information of NESP Injection. 
The medical device incidents, including those resulting from malfunctions of the device, must be 
detected, documented, and reported by the investigator throughout the study – see Section 7.4.4. 
 
6.3. 
Treatment Assignment 
The randomization schedule will be generated by GSK statistician using the randomization system 
(Randall).  
 
Subjects will be randomized centrally in a 1:1 ratio to one of the two treatment groups according to 
the randomization schedule. Randomization should precede the study treatment.  
• 
Daprodustat group 
• 
Darbepoetin alfa group 
 
Subjects will be assigned a randomization number by the Interactive Web Recognition System 
(IWRS). Once a randomization number has been assigned, it must not be re-assigned. Further details 
are provided in the Study Reference Manual (SRM).  
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
29 
 
6.4. 
Administration Schedule (Starting Dose, Dose Adjustment, and Dosing 
Frequency) 
Instructions regarding container number assignment and dose adjustments for all study treatments are 
given by the Interactive Web Recognition System (IWRS). 
 
6.4.1. 
Daprodustat 
HD subjects randomized to the daprodustat group will receive oral daprodustat according to the 
following regimen. Furthermore, these subjects will receive i.v. darbepoetin alfa placebo in the same 
manner with darbepoetin alfa.  
 
6.4.1.1. 
Starting Dose 
At Day 1, subjects will skip ESA and will start oral treatment with daprodustat at the starting dose of 
4 mg once daily and remain on the same regimen until the day of Week 4. 
 
6.4.1.2. 
Maintenance Dose 
From Weeks 4 to 52, interruption of treatment or dose adjustments will be made within the 
maintenance dose range of 1-24 mg (Table 5) according to the dose adjustment algorithm (Table 6) to 
achieve and/or maintain Hgb within the target range (10.0-12.0 g/dL) based on the HemoCue Hgb 
value measured every 4 weeks. Dose changes will be made every 4 weeks. If any of the one-step dose 
reduction criteria is met during treatment at the minimum maintenance dose (1 mg), treatment should 
be interrupted (and administer placebo); once the one-step dose increase criteria are met, treatment at 
1 mg will be resumed. If the one-step dose increase criterion is met during treatment at the maximum 
maintenance dose (24 mg), treatment at 24 mg should be continued.  
 
Table 5    Maintenance dose of daprodustat 
Dose step 
1 
2 
3 
4 
5 
6 
7 
8 
Dose level of 
daprodustat 
(once daily) 
1 mg 
2 mg 
4 mg 
6 mg 
8 mg 
12 mg 
18 mg 
24 mg 
Number of 
daprodustat 
tablets taken 
1 mg 
tablet 
×1 
2 mg 
tablet 
×1 
4 mg 
tablet 
×1 
6 mg 
tablet 
×1 
4 mg 
tablet 
×2 
6 mg 
tablet 
×2 
6 mg 
tablet 
×3 
6 mg 
tablet 
×4 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
30 
 
Table 6   Dose adjustment algorithm (daprodustat) 
Hgb 
(g/dL) 
Hgb increase over 4 weeks 
(g/dL) 
Treatment 
>13.0 
NA 
Interrupt treatment (and administer placebo) until 
Hgb decreases to less than 12.0 g/dL, and resume 
treatment at the one lower dose level 
[If interrupted (and placebo administered) at 1 mg, 
resume treatment at 1 mg after the one-step dose 
increase criterion is met] 
≥12.0 and ≤13.0 
NA 
One-step dose reduction 
≥10.0 and <12.0 
>2.0 
One-step dose reduction 
 
≤2.0 
Continue treatment at the current dose level 
≥7.5 and <10.0 
>2.0 
One-step dose reduction 
 
0.5-2.0 
Continue treatment at the current dose level 
 
<0.5 
One-step dose increase 
<7.5 
NA 
Discontinue treatment permanently* and initiate 
another appropriate treatment 
*: If an initial Hgb value is less than 7.5 g/dL, measurement will be repeated at the same study visit (using the same 
sample) to calculate the average. If the average meets the Hgb stopping criteria, study treatment will be permanently 
discontinued. 
 
6.4.2. 
Darbepoetin Alfa 
HD subjects randomized to the darbepoetin alfa group will receive intravenous darbepoetin alfa 
according to the following regimen. Furthermore, these subjects will receive oral daprodustat placebo 
in the same manner with daprodustat.  
 
6.4.2.1. 
Dose Conversion 
On Day 1, prior ESA will be replaced with darbepoetin alfa at the corresponding dose once weekly 
(Table 7). 
 
Table 7    Replacement with darbepoetin alfa - initial dose (ESA users) 
Prior ESA 
Darbepoetin alfa 
Epoetin 
≤3000 IU, per week 
15 µg, once weekly 
 
4500 IU, per week 
20 µg, once weekly 
 
6000 IU, per week 
30 µg, once weekly 
 
9000 IU, per week 
40 µg, once weekly 
Epoetin beta pegol 
≤50 µg, once every 4 weeks* 
15 µg, once weekly 
 
75 µg, once every 4 weeks* 
20 µg, once weekly 
 
100 µg, once every 4 weeks* 
30 µg, once weekly 
 
150 µg, once every 4 weeks* 
40 µg, once weekly 
 
≥200 µg, once every 4 weeks* 
60 µg, once weekly 
Darbepoetin alfa 
10, 15, 20, 30, 40, 60 µg, per week 
10, 15, 20, 30, 40, 60 µg, per week 
*: Allowance of ±1 week 
Maintenance treatment will be started at Week 2 as described in Section 6.4.2.2.  
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
31 
 
6.4.2.2. 
Maintenance Dose 
From Weeks 2 to 52, dose interruptions or adjustments will be performed within the maintenance dose 
range of 10~60 μg (Table 8) according to the dose adjustment algorithm (Table 9) so that the 
HemoCue Hgb value measured every other week will achieve or remain within the target range (10.0-
12.0 g/dL). Dose adjustments will be made once every 2 weeks. If any of the one-step dose reduction 
criteria is met during treatment at the minimum maintenance dose (10 μg), treatment should be 
interrupted (and placebo administered); once the one-step dose increase criteria are met, treatment at 
10 μg will be resumed. If the one-step dose increase criterion is met during treatment at the maximum 
maintenance dose (60 μg), treatment at 60 μg should be continued. 
 
Table 8    Maintenance dose of darbepoetin alfa 
Dose level 
1 
2 
3 
4 
5 
6 
Darbepoetin alfa 
(once weekly) 
10 µg 
15 µg 
20 µg 
30 µg 
40 µg 
60 µg 
 
Table 9  Dose adjustment algorithm (darbepoetin alfa) 
Hgb (g/dL) 
Treatment 
>13.0 
Interrupt treatment (and administer placebo) until Hgb decreases to less than 
12.0 g/dL, and resume treatment at the one lower dose level 
[If interrupted (and placebo administered) at 10 µg, resume treatment at 10 µg 
after the one-step dose increase criterion is met] 
≥12.0 and ≤13.0 
One-step dose reduction 
≥10.0 and <12.0 
Continue treatment at the current dose level* 
≥7.5 and <10.0 
One-step dose increase** 
<7.5 
Discontinue treatment permanently*** and initiate another appropriate treatment 
* If an increase of 1 g/dL is observed in 2 weeks, the dose will be reduced to the one-step lower dose level. 
** If an increase of >1 g/dL is observed in 2 weeks, treatment will be continued at the curent dose level. If there is a 
safety concern, however, the dose may be reduced at the investigator's (or subinvestigator's) discretion to the one-step 
lower dose level. 
*** If an initial Hgb value is less than 7.5 g/dL, measurement will be repeated at the same study visit (using the same 
sample) to calculate the average. If the average meets the Hgb stopping criteria, study treatment will be permanently 
discontinued. 
 
 
6.5. 
Blinding 
This will be an active-controlled, double-blind study. The study medication will be blinded through 
the study period to the subjects, investigator (or subinvestigator), study site staff and GSK study team.  
Neither the investigator (or subinvestigator) nor the subject will know which study medication the 
subject is receiving as all instructions regarding container number assignment and dose adjustment are 
given by IWRS. 
 
Roles of Person Responsible for Allocation 
The person responsible for allocation will prepare a procedure specifying the method of allocation of 
study treatment (study drug and control drug) and perform its duties in accordance with this document. 
The person responsible for allocation will confirm the indistinguishability of study treatment (study 
drug and control drug) and its package, and indicate the drug number on a study treatment (study drug 
and control drug) container. The indistinguishability of study treatment (study drug and control drug) 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
32 
 
and its package should be checked again after completion of the study. Furthermore, the person 
responsible for allocation will prepare a procedure for case of an emergency that knowledge of the 
study treatment is essential, and break the key code of only the treatment concerned, as per request. 
 
Emergency Unblinding 
• 
The investigator or treating physician may unblind a subject’s treatment assignment only in the 
case of an emergency OR in the event of a serious medical condition when knowledge of the 
study treatment (daprodustat or darbepoetin alfa) is essential for the appropriate clinical 
management or welfare of the subject as judged. 
• 
Investigators (or subinvestigators) have direct access to the subject’s individual study treatment. 
• 
It is preferred (but not required) that the investigator (or subinvestigator) first contacts the 
Medical Monitor or appropriate GSK study personnel to discuss options before unblinding the 
subject’s treatment assignment. 
• 
If GSK personnel are not contacted before the unblinding, the investigator (or subinvestigator) 
must notify GSK as soon as possible after unblinding, but without revealing the treatment 
assignment of the unblinded subject, unless that information is important for the safety of 
subjects currently in the study. 
• 
The date and reason for the unblinding must be fully documented in an appropriate page of the 
CRF by the investigator (or subinvestigator). 
• 
Further details of unblinding is provided in the SRM. 
 
A subject will be withdrawn if the subject’s treatment code is unblinded by the investigator (or 
subinvestigator). The primary reason for discontinuation (the event or condition which led to the 
unblinding) will be recorded in the CRF. 
 
• 
GSK’s Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the treatment 
assignment for any subject with an SAE. If the SAE requires that an expedited regulatory report 
be sent to one or more regulatory agencies, a copy of the report, identifying the subject’s 
treatment assignment, may be sent to investigators in accordance with local regulations and/or 
GSK policy. 
 
 
6.6. 
Packaging and Labeling 
The contents of the label will be in accordance with all applicable regulatory requirements. 
 
6.7. 
Preparation/Handling/Storage/Accountability 
• 
No special preparation of study treatment is required.  
• 
Only subjects enrolled in the study may receive study treatment and only authorized site staff 
may supply or administer study treatment. All study medications must be stored in a secure 
environmentally controlled and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the investigator (or subinvestigator) and 
authorized site staff. 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
33 
 
• 
Subjects must bring all of supplied study medication bottles of daprodustat/placebo at every 4 
week’s study visit. Study staff will collect all of study medication bottles supplied at the previous 
study visit and supply new study medication bottles.  
• 
The investigator (or subinvestigator), institution, or the head of the medical institution (where 
applicable) is responsible for study treatment accountability, reconciliation, and record 
maintenance (i.e. receipt, reconciliation and final disposition records).  
• 
Under normal conditions of handling and administration, study medication is not expected to 
pose significant safety risks to site staff.  
• 
GSK will provide a document describing occupational hazards and recommended handling 
precautions either to the investigator (or subinvestigator) when necessary or upon request of the 
medical institution.  
• 
Further details are provided in the SRM.  
 
6.8. 
Compliance with Study Treatment Administration 
Daprodustat 
Since daprodustat is self-administered, compliance with daprodustat treatment will be assessed 
through an interview with subjects at each study visit and recorded in the source document and eCRF. 
A record of the number of daprodustat tablets dispensed to and taken by each subject will be 
maintained and reconciled with study treatment and compliance records. In addition, the number of 
daprodustat doses dispensed, used, and unused, as well as study treatment start and stop dates will be 
recorded in the source document and eCRF (the number of doses returned and unreturned will also be 
recorded separately). 
Darbepoetin alfa 
Darbepoetin alfa will be administered to subjects once weekly at the site. Dosing details will be 
recorded in the source document and eCRF. Administration of darbepoetin alfa will be performed at 
the scheduled visit dates in principle.  
 
6.9. 
Treatment of Study Treatment Overdose 
For the purposes of this study, an overdose of daprodustat is defined as any dose greater than the 
highest daily dose included in the protocol. There is no specific antidote for overdose with daprodustat. 
The expected manifestations of daprodustat overdosage include signs and symptoms associated with 
an excessive and/or rapid increase in Hgb concentration. Daprodustat is highly protein bound; thus, 
clearance of unchanged daprodustat by hemodialysis or peritoneal dialysis is very low and these are 
not effective methods to enhance the elimination of daprodustat. Daprodustat metabolites are, in part, 
cleared via hemodialysis. In the event of a suspected overdose, it is recommended that the appropriate 
supportive clinical care be instituted, as dictated by the subject’s clinical status. Additionally, subjects 
should be monitored closely for cardiovascular events, increased heart rate and hematologic 
abnormalities. 
 
Consult the respective approved Prescribing Information for information on overdose for darbepoetin 
alfa. 
 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
34 
 
6.10. Treatment after the End of the Study 
Since the target disease studied is not life-threatening or severely debilitating and there is the 
alternative therapy, subjects will not receive any additional treatment from GSK after completion of 
the study. The investigator (or subinvestigator) is responsible for ensuring that consideration has been 
given to post-study care of the subject’s medical condition, whether or not GSK is providing specific 
post-study treatment. 
 
6.11. Concomitant Medications and Non-Drug Therapies 
Concomitant medications, including over-the-counter medications and supplements, taken during the 
study will be recorded in the eCRF. Drug names and start/stop dates will be recorded for general 
concomitant medications, while additional details, including dose, route of administration, and dosing 
frequency, will be recorded for certain medications (e.g., ESAs, iron, anti-hypertensive medications). 
Further details are provided in the SRM. 
 
6.11.1. 
Permitted Medications and Non-Drug Therapies 
Unless specified as a prohibited medication in Section 6.11.2, all concomitant medications should be 
considered permitted provided they are not contraindicated for the individual subject concerned. 
Regular multivitamins (at recommended daily allowance) and other supplements such as calcium and 
vitamin D may be used if permitted by the investigator or his/her designee.  
CYP2C8 is involved in the primary route of metabolism of daprodustat. Accordingly, co-
administration of daprodustat with moderate CYP2C8 inhibitors (e.g., clopidogrel, teriflunomide, 
deferasirox) should be performed with caution. 
Antihyperphosphatemic agents containing iron (e.g., ferric citrate hydrate) may be started from 
Week 4 onwards unless any other antihyperphosphatemic agents are appropriate. Once started, iron-
containing antihyperphosphatemic agents must be continued until the end of the study wherever 
possible.  
 
6.11.2. 
Prohibited Medications and Non-Drug Therapies 
Use of any of the following drugs from screening until 7 days after the last dose of study treatment is 
prohibited: 
• 
Strong inhibitors of CYP2C8 (e.g., gemfibrozil) 
• 
Strong inducers of CYP2C8 (e.g., rifampin/rifampicin) 
 
Use of the following drug; during the treatment period: 
• 
Erythropoietin (e.g., epoetin/ darbepoetin alfa/ epoetin beta pegol) 
 
Note: excluding darbepoetin alfa (brand name: Nesp) supplied by GSK. 
 
6.12. Supplemental Iron Therapy 
From Week 4, Supplemental iron therapy will be administered according to the Guidelines for Renal 
Anemia [The Japanese Society for Dialysis Therapy , 2016] if ferritin is ≤100 ng/mL and TSAT is 
≤20%. The investigator (or subinvestigator) can choose the route of administration and dose of 

2015N266251_02 
 
CONFIDENTIAL 
 
 
 
PHI201754 
35 
 
prescription iron, and they should consider to discontinue their patient’s iron therapy if ferritin is 
≥300 ng/mL [The Japanese Society for Dialysis Therapy , 2016]. 
Refer to 4.2. regading iron use until Week 4.    
 
 
7. Study Assessments and Procedures 
Protocol waivers or exemptions are not allowed with the exception of immediate safety concerns. 
Therefore, adherence to the study design requirements, including those specified in the Time and 
Events Table, are essential and required for study conduct. 
 
7.1. 
Time and Events Table 
The time and events tables for the entire study and PK assessment are presented as Table 10 and Table 
11, respectively. Throughout the study period, including the screening, treatment and follow-up 
periods, the study visit days should occur on the first dialysis session day of the week (e.g., if 
Monday-Wednesday-Friday schedule, the study visit should be on Monday) and Visit days will be 
counted from Day 1. To allow for a flexible schedule, the allowable window for Screening Visit will 
be “2-4 weeks ± 3 days prior to Day 1”, and that for the visits after Day 1 will be “± 3 days”.  In any 
case, the study visit should occur on the first dialysis session day of the week. Unless otherwise 
specified, all assessments should occur before dialysis on the day. 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
36 
 
Table 10    Time and Events Table 
Phase 
Screening 
Treatment 
Visit 
 
All assessments pre-dialysis, unless noted. 
-4～-2 11 
Day 1 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
22 
24 
26 
28 
Allowance range (days) 
±3 
- 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history, demography, height1, 
weight 1 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Registration with IWRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study medication dispensing 2, 3 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study treatment compliance 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs (before and after dialysis) 4 
X 
X 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
Ophthalmology 5 
X12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
HemoCue Hgb 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology 
X 
X 
 
X 
 
Hgb 
only 
 
Hgb 
only 
 
X 
 
Hgb 
only 
 
Hgb 
only 
 
X 
Clinical chemistry 
X 
X 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
Pregnancy test (serum hCG) 6 
X 
X 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
Estradiol, FSH 7 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PK 8 
 
 
 
 
 
 
 
X 
 
 
 
 
 
X 
 
 
Ferritin, TSAT 
X 
X 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
Serum iron, TIBC, UIBC, serum transferrin, 
hepcidin 
 
X 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
iPTH 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
HR-QoL (SF-36, EQ-5D-5L/ EQ-VAS) 
 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
X 
Genetics sample 9 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE assessment 10 
X 13 
 
Concomitant Medications Review 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
37 
 
Phase 
Treatment 
Follow-up 
Visit 
 
All assessments pre-dialysis, unless noted. 
30 
32 
34 
36 
38 
40 
42 
44 
46 
48 
50 
52 
Early 
withdrawal 
14 
2 weeks  
after Week 52 
or early 
withdrawal 
Allowance range (days) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
- 
±3 
Informed consent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history, demography, height1, 
weight 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Registration with IWRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Study medication dispensing 2, 3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
Study treatment compliance 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Vital signs (before and after dialysis) 4 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
X 
Ophthalmology 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
HemoCue Hgb 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Hematology 
 
Hgb 
only 
 
Hgb 
only 
 
X 
 
Hgb 
only 
 
Hgb 
only 
 
X 
X 
X 
Clinical chemistry 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
X 
Pregnancy test (serum hCG) 6 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
X 
Estradiol, FSH 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PK 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ferritin, TSAT 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
 
Serum iron, TIBC, UIBC, serum transferrin, 
hepcidin 
 
 
 
 
 
X 
 
 
 
 
 
X 
X 
 
iPTH 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
HR-QoL 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
Genetics sample 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE assessment 10 
 
Concomitant Medications Review 
 
1. 
Body weight is measured after dialysis. Both height and body weight are measured only at screening. 
2. 
Daprodustat/placebo will be dispensed once every 4 weeks, and darbepoetin alfa/placebo will be dispensed once every 2 weeks 
3. 
If a subject visit the study site only to receive study medication, only registration with the IWRS  study medication dispensing, and study medication compliance will be required.  

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
38 
 
4. 
At visits without dialysis, only one measurement of each parameter will be obtained. 
5. 
Ophthalmology exams should be conducted at the following time points. 
• 
Screening: anytime after consenting and prior to first dose of study medication (Day 1) 
• 
Week 12: window from weeks 10-14 (inclusive) 
• 
End of study: window from weeks 48-52 (inclusive) 
• 
Early study medication discontinuation: withdrawal eye exam as close to the last dose as possible (the repeat exams are not required if one has been performed within the 2 prior weeks). 
6. 
Performed in females of childbearing potential. 
7. 
Measured in female subjects only to determine the menopausal status (see Section 5.1.) 
8. 
See Table 11. 
9. 
Informed consent for optional Genetic research should be obtained before collecting a sample (see Section 7.6.). 
10. See Section7.4.1.1.. 
11. The interval between screening and Day 1 should be 4 weeks in subjects treated with epoetin beta pegol every 4 weeks or darbepoetin alfa every 4 weeks in the prior ESA therapy. 
12. For re-screening subjects, no repeated ophthalmology exams could be required at re-screening, in which case the results of ophthalmology exams at the most recent screening could be replaced on the 
investigator’s (or subinvestigator’s) discretion if re-screening subjects meet all of the following criteria: 
• 
There were no findings that would suggest a repeat ophthalmology exam performed within the next 3 months at the latest screening ophthalmology exam. 
• 
No new ocular symptoms or complaints were noted after the most recent ophthalmologic screening and before the next re-screening. 
• 
The most recent ophthalmology screening was performed within 3 months prior to anticipated Day 1. 
13. Only SAEs assessed as related to study participation or a GSK product are collected. 
14. For withdrawn subjects, specified assessments should be done wherever possible.  
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
39 
 
Table 11    Blood Sampling Schedule for Pharmacokinetics 
PK sample 
Week 12 2 
Week 24 2 
Blood sampling timing 1 
1, 2, 3, and 4 h after administration of daprodustat or placebo 
Subjects must take the study medication with regard to blood sampling time. Subjects will record the date and time of the last two 
study medication doses taken prior to blood sampling in the medication diary. There should be an interval of at least 12h (preferably, 
almost 24 h) between these two doses. 
1. 
Blood sampling should be completed within +/- 30 min of the planned collected time. 
2. 
Blood sampling not performed at this visit may be postponed until the following visits.  
 
7.2. 
Screening and Critical Baseline Assessments 
Cardiovascular medical history/risk factors will be assessed (documented in the eCRF) at baseline. 
In addition, the following demographic information will be collected: 
• 
Year of birth 
• 
Gender 
• 
Race and ethnic 
• 
Medical history/treatment history/family history will be assessed in relation to the 
inclusion/exclusion criteria (Section 5.1, 5.2).  
 
Full details of baseline assessments are provided in Time and Events Table (Table 10).  
 
7.3. 
Efficacy 
Efficacy will be assessed according to the Time and Event Table (Table 10).  
Hgb concentrations measured by the central laboratory will be mainly used for efficacy assessment.  
GSK will supply a point-of-care Hgb analyzer (HemoCue) to each site for rapid and convenient 
measurement of Hgb and to ensure consistency of Hgb measurements across all sites participating in 
the study. Assessment for Hgb concentrations via HemoCue will be used for eligibility (Section 5.1), 
permanent discontinuation of study treatment (Section 5.4), and dose adjustment criteria (Section 6.4).  
In addition, assessments of iron metabolism parameters used for exploratory assessment is outlined 
with specific procedures in Section 7.4.7.  
 
7.4. 
Safety 
Planned time points for all safety assessments are listed in the Time and Events Table (Table 10).  
Additional time points for safety tests (such as vital signs, physical exams and laboratory safety tests) 
may be added during the course of the study based on newly available data to ensure appropriate 
safety monitoring 
 
7.4.1. 
Adverse Events (AE) and Serious Adverse Events (SAEs) 
The definitions of an AE or SAE can be found in Section 12.6. Appendix 6. 
The investigator and their designees are responsible for detecting, documenting and reporting events 
that meet the definition of an AE or SAE. 
 
7.4.1.1. 
Time period and Frequency for collecting AE and SAE information 
• 
AEs and SAEs will be collected from the start of Study Treatment until the follow-up contact 
(see Section 7.4.1.3.), at the timepoints specified in the Time and Events Table (Table 10). 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
40 
 
• 
Medical occurrences that begin prior to the start of study treatment but after obtaining informed 
consent may be recorded on the Medical History/Current Medical Conditions section of the CRF. 
• 
Any SAEs assessed as related to study participation (e.g., protocol-mandated procedures, 
invasive tests, or change in existing therapy) or related to a GSK product will be recorded from 
the time a subject consents to participate in the study up to and including any follow-up contact.  
• 
All SAEs will be recorded and reported to GSK within 24 hours, as indicated in Section 12.6. 
Appendix 6. 
• 
Investigators are not obligated to actively seek AEs or SAEs in former study subjects. However, 
if the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the study 
treatment or study participation, the investigator must promptly notify GSK. 
• 
 
NOTE: The method of recording, evaluating and assessing causality of AEs and SAEs plus procedures 
for completing and transmitting SAE reports to GSK are provided in Section 12.6. Appendix 6. 
 
7.4.1.2. 
Method of Detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and non-
leading verbal questioning of the subject is the preferred method to inquire about AE occurrence.  
Appropriate questions include: 
• 
“How are you feeling?”  
• 
“Have you had any (other) medical problems since your last visit/contact?” 
• 
“Have you taken any new medicines, other than those provided in this study, since your last 
visit/contact?” 
 
7.4.1.3. 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs, and non-serious AEs of special interest (as defined in Section 
7.4.2.) will be followed until resolution, until the condition stabilizes, until the event is otherwise 
explained, or until the subject is lost to follow-up (as defined in Section5.4.). Further information on 
follow-up procedures is given in Section 12.6. Appendix 6.. 
 
 
7.4.1.4. 
Cardiovascular and Death Events 
For any cardiovascular events detailed in Section 12.6. Appendix 6 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF will be required to 
be completed.  These sections include questions regarding cardiovascular (including sudden cardiac 
death) and non-cardiovascular death.  
The CV CRFs are presented as queries in response to reporting of certain CV Medical Dictionary for 
Regulatory Activities (MedDRA) terms.  The CV information should be recorded in the specific 
cardiovascular section of the CRF within one week of receipt of a CV Event data query prompting its 
completion.   

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
41 
 
The Death CRF is provided immediately after the occurrence or outcome of death is reported. Initial 
and follow-up reports regarding death must be completed within one week of when the death is 
reported. 
 
7.4.1.5. 
Regulatory Reporting Requirements for SAEs 
Prompt notification by the investigator to GSK of SAEs and non-serious AEs related to study 
treatment (even for non- interventional post-marketing studies) is essential so that legal obligations 
and ethical responsibilities towards the safety of subjects and the safety of a product under clinical 
investigation are met.  
 
GSK has a legal responsibility to notify both the local regulatory authority and other regulatory 
agencies about the safety of a product under clinical investigation. GSK will comply with country 
specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC) and investigators. 
 
Investigator safety reports are prepared for suspected unexpected serious adverse reactions according 
to local regulatory requirements and GSK policy and are forwarded to investigators as necessary. 
 
An investigator who receives an investigator safety report describing a SAE(s) or other specific safety 
information (e.g., summary or listing of SAEs) from GSK will file it with the IB and will notify the 
IRB/IEC, if appropriate according to local requirements. 
 
7.4.2. 
Adverse Events of Special Interest 
The investigator (or subinvestigator) or designee will be responsible for detecting, documenting, and 
reporting any AEs of special interest listed below. These events have been identified based on the 
known safety profiles of ESAs, theoretical or potential risks based on the mechanism of action of 
daprodustat, and findings from completed nonclinical studies of daprodustat.  
 
• 
Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis  
• 
Death, myocardial infarction, stroke, heart failure, thromboembolic events, thrombosis of 
vascular access 
• 
Cardiomyopathy   
• 
Pulmonary artery hypertension (PAH) 
• 
Cancer-related mortality and tumor progression and recurrence  
• 
Esophageal and gastric erosions 
• 
Proliferative retinopathy, macular edema, choroidal neovascularization  
• 
Exacerbation of rheumatoid arthritis 
 
Any relevant AE should be recorded in the relevant section of the subject’s eCRF. 
 
7.4.3. 
Pregnancy 
• 
Details of all pregnancies in female subjects will be collected after the start of dosing and until 
the follow-up contact. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
42 
 
• 
If a pregnancy is reported then the investigator should inform GSK within 2 weeks of learning of 
the pregnancy and should follow the procedures outlined in Section 12.4.. Appendix 4. 
 
 
7.4.4. 
Medical Device Incidents (Including Malfunctions) 
The medical devices (i.e., the darbepoetin alfa plastic prefilled syringes) are being provided for use in 
this study. The investigator is responsible for the detection and documentation of events meeting the 
definitions of incident or malfunction that occur during the study with such devices.  
The definition of a Medical Device Incident can be found in Appendix 8 (Section 12.8.) 
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes outlined in 
Section 7.4.1. and Appendix 6 (Section 12.6) of the Protocol. 
 
7.4.4.1. 
Time Period for Detecting Medical Device Incidents 
• 
Medical device incidents or malfunctions of the device that result in an incident will be detected, 
documented and reported during all periods of the study in which the medical devices are 
available for use.  
• 
If the investigator learns of any incident at any time after a subject has been discharged from the 
study, and such incident is reasonably related to a medical device provided for the study, the 
investigator will promptly notify GSK.  NOTE: The method of documenting Medical Device 
Incidents is provided in Appendix 8 (Section 12.8). 
 
7.4.4.2. 
Follow-up of Medical Device Incidents 
• 
All medical device incidents involving an AE, will be followed until resolution of the event, until 
the condition stabilizes, until the condition is otherwise explained, or until the subject is lost to 
follow-up (as defined in Section 5.4.). This applies to all subjects, including those withdrawn 
prematurely.  
• 
The investigator is responsible for ensuring that follow-up includes any supplemental 
investigations as may be indicated to elucidate as completely as practical the nature and/or 
causality of the incident. 
• 
New or updated information will be recorded on the originally completed form ”Medical Device 
Incident Report Form” with all changes signed and dated by the investigator. 
 
7.4.4.3. 
Prompt Reporting of Medical Device Incidents to GSK 
• 
Medical device incidents will be reported to GSK within 24 hours once the investigator 
determines that the event meets the protocol definition of a medical device incident. 
• 
Facsimile transmission of the "Medical Device Incident Report Form" is the preferred method to 
transmit this information to the SAE contact information. 
• 
The same individual will be the contact for receipt of medical device reports and SAEs. 
• 
In the absence of facsimile equipment, notification by telephone is acceptable for incidents, with 
a copy of the "Medical Device Incident Report Form" sent by overnight mail. 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
43 
 
7.4.5. 
Vital Signs/Height/Weight 
Systolic and diastolic blood pressure and heart rate will be measured before and after dialysis, in 
sitting or semi-supine position (chair for dialysis is acceptable) after at least 5 minutes rest. When 
measuring before dialysis, it should be conducted prior to blood sampling for lab tests. One reading of 
blood pressure and heart rate will be taken and recorded in the source document and the CRF. Height 
and weight will be measured at screening visit only. Weight should be measured after dialysis. 
 
7.4.6. 
Electrocardiogram (ECG) 
12-lead ECGs will be recorded in supine position. The heart rate, PR, QRS, and QT (pre-corrected) 
intervals will be measured.  QTcB should be calculated by machine or manually by designated staff 
at each site. The investigator determines whether the ECG data is assessable or not. Measurement 
method and measurement timing (i.e., before or after dialysis) should be consistent as far as possible 
during the study period. 
At Screening visit when an ECG is performed, two additional ECGs are required if initial ECG 
indicates prolonged QTc. The average QTcB value of all three ECGs will be used to determine 
eligibility. 
QTc exclusion criteria can be found in Section 5.2.  Refer to SRM for further details. 
 
7.4.7. 
Clinical Laboratory Assessments 
All study-required laboratory assessments will be performed by a central laboratory with the exception 
of HemoCue Hgb. The results of each HemoCue Hgb must be entered into the subject’s eCRF. Details 
are provided in the SRM.  
All laboratory assessments, as defined in Table 12, must be conducted in accordance with the 
Laboratory Manual and Protocol Time and Events Schedule (Table 10). Laboratory requisition forms 
must be completed and samples must be clearly labeled with the subject number, protocol number, 
site/center number, and sample collection date. Reference ranges for all parameters will be provided to 
the site by the central laboratory. Details of blood sampling (including the volume of blood to be 
collected) as well as procedures for processing, storage, and shipment of samples are provided in the 
SRM.  
PK assessment of daprodustat is outlined in Section 7.5. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
44 
 
 
Table 12    Laboratory Assessments 
Laboratory 
assessment 
Parameter 
Hematology 
Platelet count 
RBC indices: 
WBC dfferential 
RBC count 
MCV 
Neutrophils 
Reticulocyte count 
MCH 
Lymphocytes 
Hemoglobin 
MCHC 
Monocytes 
Hematocrit 
RDW 
Eosinophils 
WBC count 
 
Basophils 
Clinical chemistry 
Sodium 
AST 
Bicarbonate 
Potassium 
ALT 
Inorganic phosphate 
Chloride 
Creatinine 
Glucose 
Calcium (total and albumin-
corrected) 
Total bilirubin 
Direct/indirect bilirubin  
Albumin 
Urea nitrogen 
 
Total cholesterol 
HDL cholesterol 
LDL cholesterol 
Iron parameters 
Serum iron 
Serum ferritin 
Serum transferrin 
TIBC 
UIBC 
TSAT 
Hepcidin 
 
 
Other laboratory 
tests 
FSH 1 
Estradiol 1 
iPTH 
serum hCG 2 
 
 
1. 
Measured in female subjects only to determine the menopausal status (see Section 5.1). 
2. 
Performed in females of childbearing potential.  
 
If additional non-protocol specified laboratory assessments are performed at the institution’s local 
laboratory and result in a change in subject management or are considered clinically significant by the 
investigator (or subinvestigator) (e.g., SAE or AE or dose modification), the results must be recorded 
in the eCRF. 
Refer to the SRM for appropriate processing and handling of samples to avoid duplicate and/or 
additional blood draws. 
 
All laboratory tests with values that are considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline. If such 
values do not return to normal within a period judged reasonable by the investigator (or 
subinvestigator), the etiology should be identified and the Sponsor notified. 
 
7.4.8. 
Ophthalmology 
Ophthalmology exams will be performed by a study-designated ophthalmology specialist. Each 
assessment will include a comprehensive eye exam with at least the following components: 
measurement of best corrected visual acuity, intraocular pressure, an anterior chamber exam, and a 
fundoscopic exam. These exams will be used for assessment of ocular adverse events. Assessment 
results will be captured on worksheets which will be transferred to the eCRF. Additional details on the 
process for completing these assessments are provided in the SRM. 
 
7.5. 
Pharmacokinetics 
Blood samples for PK analysis of daprodustat will be collected as outlined in Table 11, and the date 
and time of the last two study medication doses taken prior to blood sampling as well as the date and 
time of sampling must be recorded in the eCRF.  

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
45 
 
Blood PK analysis will be performed under the control of GSK Platform Technologies and Science-
Drug Metabolism and Pharmacokinetics (PTS-DMPK)/Scinovo and GSK-Japan Bioanalysis, the 
details of which will be included in the SRM. Concentrations of parent daprodustat will be determined 
in blood samples using the currently established analytical methodology. Raw data will be archived at 
the bioanalytical site. 
Procedures for processing, storage, and shipment of samples are provided in the SRM.  
 
7.6. 
Genetics 
A blood sample will be collected for genetic analysis from consenting subjects. This sample can be 
collected on Day 1 once written informed consent has been obtained. Information regarding genetic 
research is included in Section 12.7. Appendix 7. 
 
7.7. 
Patient Reported Outcome (PRO)  
The patient reported outcome (PRO) [e.g.health-related QOL (HRQoL), health status and health 
utility] will be assessed using several rating scales.  
 
All questionnaires used in this study have been translated into Japanese and are validated and will be 
administered in paper version.  
Specific instructions on how the subject is to complete the scales and the process for data entry are 
provided in the SPM. 
 
7.7.1. 
Health Related Quality of Life (SF-36)  
The SF-36 acute version is a general health status questionnaire designed to elucidate the patient’s 
perception of his/her health on several domains, including physical functioning, role physical, bodily 
pain, vitality, social functioning, role emotional, mental health, and general health over the past seven 
days. The questionnaire contains 36 Likert type questions that ask the patient to recall how he/she felt 
during the past seven days. 
• 
 
7.7.2. 
EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L)/ EuroQol Visual 
Analogue Scale (EQ-VAS) 
The EQ-5D-5L is intended to measure the general health status and health utility. The EQ-5D-5L 
consists of 2 concepts: self-reported health status consisting of five dimensions (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses (no 
problems/slight problems/moderate problems/severe problems/extreme problems) and self-rated 
health utility on a visual analogue scale (VAS),from ‘best imaginable health state’ and ‘worst 
imaginable health state’.  
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
46 
 
8. DATA MANAGEMENT 
• 
For this study subject data will be entered into GSK defined CRFs, transmitted electronically to 
GSK or designee and combined with data provided from other sources in a validated data system. 
• 
Management of clinical data will be performed in accordance with applicable GSK standards and 
data cleaning procedures to ensure the integrity of the data, e.g., removing errors and 
inconsistencies in the data. 
• 
Adverse events and concomitant medications terms will be coded using MedDRA and an internal 
validated medication dictionary, GSKDrug.   
• 
CRFs (including queries and audit trails) will be retained by GSK, and copies will be sent to the 
investigator to maintain as the investigator copy. Subject initials will not be collected or 
transmitted to GSK according to GSK policy. 
 
 
9. STATISTICAL CONSIDERATIONS AND DATA ANALYSES 
A detailed description of any planned analyses will be documented in a RAP. Any deviations from the 
analyses described in the protocol will be documented in the RAP or the final study report.  
 
9.1. 
Hypotheses 
The primary objective of the study is to demonstrate the non-inferiority of daprodustat to darbepoetin 
alfa based on mean Hgb during the primary efficacy evaluation period (Weeks 40 to 52) in HD 
subjects. As a preliminary assessment, it will be confirmed whether the lower and upper limit of 95% 
CI for mean Hgb during the primary efficacy evaluation period in daprodustat group would be in 
target range (10.0-12.0 g/dL) at first. And then the following non-inferiority statistical hypotheses are 
to be tested at a one-sided significance level of 2.5% (i.e. two-sided significance level of 5%): 
 
• 
H0: Treatment difference in mean Hgb during the primary efficacy evaluation period is -1.0 g/dL 
or less. 
• 
H1: Treatment difference in mean Hgb during the primary efficacy evaluation period is greater 
than -1.0 g/dL. 
 
Only when the primary endpoint achieves non-inferiority, statistical testing will progress to the 
principal secondary endpoint with a focus on superiority according to the step-down procedure. More 
specifically, the superiority of daprodustat to darbepoetin alfa in terms of target Hgb control in HD 
subjects is to be demonstrated at a two-sided significance level of 5% by testing the following 
statistical hypotheses: 
 
• 
H0: The proportion of subjects whose mean Hgb during the primary efficacy evaluation period is 
within the target range (10.0-12.0 g/dL) is equal between the treatment groups. 
• 
H1: The proportion of subjects whose mean Hgb during the primary efficacy evaluation period is 
within the target range (10.0-12.0 g/dL) is different between the treatment groups.  
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
47 
 
9.2. 
Sample Size Considerations 
9.2.1. 
Sample Size Assumptions 
Assuming a non-inferiority margin of -1.0 g/dL, a treatment difference of 0.0 g/dL, and a standard 
deviation of 1.5 g/dL for mean Hgb during the primary efficacy evaluation period in HD subjects, 
two-sample t-test has at least 99% power at a one-sided significance level of 2.5% (i.e. two-sided 
significance level of 5%) with a sample size of 100 subjects per group. Assuming a dropout rate of 
approximately 25%, 135 subjects will be randomized to each group. Given the results from previous 
non-inferiority studies of similar drugs (darbepoetin alfa, epoetin beta pegol, and peginesatide), the 
non-inferiority margin of -1.0 g/dL is set. Since an increase of 1.0 g/dL indicates improvement in 
anemia according to the guidelines for renal anemia in Japan, the non-inferiority margin of -1.0 g/dL 
may be the clinically acceptable largest difference in renal anemia.   
While the present study is designed to ensure long-term safety data from 100 HD subjects, and the 
primary hypothesis test has at least 99% power to estimate the efficacy very precisely, non-inferiority 
can be statistically demonstrated with a minimum between-group difference of -0.582 g/dL.  
 
9.2.2. 
Sample Size Sensitivity 
The power is shown according to treatment difference and standard deviation in Table 13.  
 
Table 13    Power Sensitivity (100 Subjects Evaluated, Noninferiority Margin of -1.0, 
One-Sided Significance Level of 2.5%) 
Treatment 
difference 
Standard deviation 
1.25 
1.5 
1.75 
0 
100.0% 
99.7% 
98.0% 
-0.1 
99.9% 
98.8% 
95.1% 
-0.2 
99.5% 
96.4% 
89.6% 
-0.3 
97.6% 
90.7% 
80.4% 
 
9.2.3. 
Sample Size Re-estimation or Adjustment 
No sample size re-estimation is planned for this study.  
 
9.3. 
 Data Analysis Considerations 
9.3.1. 
Analysis Populations 
• 
All Screening Population 
The All Screening Population consists of all subjects who are given subject number and whose data 
are collected, including demographics at screening. 
 
• 
Intention-To-Treat (ITT) Population 
The ITT Population consists of all subjects who are given a randomization number regardless of 
whether they actually receive study treatment and whose Hgb assessment was performed at baseline 
and at least one scheduled post-baseline visit. Subjects will be analyzed according to randomized 
treatment. This population will be the primary population for an assessment of non-inferiority. 
 
• 
modified ITT (mITT) Population 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
48 
 
The mITT Population consists of all ITT subjects who have at least one Hgb measurement during the 
efficacy evaluation period. Subjects will be analyzed according to randomized treatment. This 
population will be the primary population for an assessment of superiority.  
 
• 
Per-Protocol (PP) Population 
The PP Population consists of all mITT subjects who are not major protocol violators. Details will be 
defined in the RAP. This population will be used for efficacy sensitivity analyses.  
 
• 
Safety Population 
The Safety Population consists of subjects who receive at least one dose of study treatment. Subjects 
will be analyzed according to the treatment received. This population will be used for safety analyses.  
 
• 
PK Population 
The PK Population consists of all daprodustat -treated subjects from whom PK samples are collected 
and analyzed.  
 
Additional populations may be defined in the RAP. 
 
9.3.2. 
Interim Analysis 
No interim analysis is planned.  
 
9.3.3. 
Adjustment for Multiplicity 
Adjustment for multiplicity will be applied to maintain an overall type I error rate of 5%. After a 
preliminary assessment, the primary endpoint will be evaluated to demonstrate the non-inferiority at a 
one-sided significance level of 2.5% (i.e. two-sided significance level of 5%). Only when the primary 
endpoint achieves non-inferiority, statistical testing will progress to the principal secondary endpoint 
with a focus on superiority. Since the process will follow step-down manner, a multiplicity adjustment 
will not be needed according to a closed test procedure, similarly two-sided significance level of 5% 
will be used.  
Other secondary endpoints, which will be evaluated on a complementary or exploratory basis, will be 
compared at a two-sided significance level of 5% without multiplicity adjustment.  
 
9.4. 
Key Elements of Analysis Plan 
9.4.1. 
Primary Efficacy Analysis 
The primary endpoint, which is the mean Hgb during the primary efficacy evaluation period, will be 
analyzed to demonstrate the non-inferiority of daprodustat to darbepoetin alfa in HD subjects.  
MMRM will be used to estimate the mean Hgb during the primary efficacy evaluation period and its 
95% CI by treatment groups. This model includes treatment groups, baseline Hgb, assessment visits, 
interaction terms between treatment groups and assessment visits, as well as interaction terms between 
baseline Hgb and assessment visit. As a preliminary assessment, it will be confirmed if the lower and 
upper limit of 95% CI for mean Hgb during the primary efficacy evaluation period in daprodustat 
group would be in target range (10.0- 12.0 g/dL) at first. This confirmation will be established if the 
lower and upper limit of 95% CI for the mean Hgb in daprodustat group based on observed Hgb 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
49 
 
would lie fully within target range (10.0-12.0 g/dL). In addition, the point estimate and 95% CI for the 
treatment difference (daprodustat - darbepoetin alfa) in the mean Hgb during the primary efficacy 
evaluation period will be estimated. Non-inferiority will be established if the lower limit of the 95% 
CI is greater than -1.0 g/dL. Even if the 95% CI for the difference is completely negative (i.e. lies fully 
within the range -1.0 to <0 g/dL) non-inferiority would still be concluded on condition that the mean 
Hgb estimated in the daprodustat group is within the target range. 
The primary efficacy population will be the ITT Population, and the analysis will be repeated in the 
mITT and PP Population to evaluate the robustness of the conclusion. Following sensitivity analyses 
will be conducted to assess robustness of study result.  
• 
If there are Hgb considered to be impacted by blood transfusion or marketed rhEPO/ESAs, 
sensitivity analysis excluding the Hgb values from the analyses of primary endpoint will be 
conducted. 
• 
Analysis of covariance (ANCOVA) will be conducted as sensitivity analysis to MMRM. This 
model includes treatment group and baseline Hgb. The analysis population will be mITT 
population and the similar analysis will be repeated in the PP population. 
• 
A tipping point analysis based on multiple imputation will be conducted as sensitivity analysis to 
missing data assumption. This analysis explores a point where non-inferiority is not confirmed 
(tipping point) by changing assumption to missing data and repeating imputation. The analysis 
population will be ITT population and the similar analysis will be repeated in the mITT and PP 
population. 
Further details of sensitivity analyses will be provided in the RAP. 
 
9.4.2. 
Principal Secondary Efficacy Analysis 
The principal secondary endpoint, which is the proportion of subjects whose mean Hgb during the 
primary efficacy evaluation period is within the target range, will be analyzed to demonstrate the 
superiority of daprodustat to darbepoetin alfa in HD subjects.  
In the mITT Population, a logistic regression model including treatment group and baseline Hgb as 
covariates will be used to estimate the point estimate and 95% CI for the odds ratio (daprodustat/ 
darbepoetin alfa). This analysis will be performed to demonstrate the superiority at a two-sided 
significance level of 5%, conditional on the primary endpoint achieving noninferiority.  Superiority 
will be established if the lower limit of the 95% CI for odds ratio is greater than 1.0. 
 
9.4.3. 
Other Secondary Efficacy Analyses 
Among the secondary efficacy endpoints, the time (%) in Hgb target range during the primary efficacy 
evaluation period , and proportion of subjects who have an Hgb increase of more than 2 g/dL over any 
4 weeks, the point estimates and 95% CIs for the treatment difference (or odds ratio) in HD subjects 
will be calculated. Other secondary efficacy and exploratory endpoints will be summarized by each 
treatment group.  
 
9.4.4. 
Safety Analyses 
In principle, safety data will be summarized by each treatment group in the Safety Population.  
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
50 
 
9.4.4.1. 
Exposure 
Exposure information will be listed for all subjects. The duration of treatment (number of days) and 
cumulative dose will be tabulated. In addition, distribution of the dose level at each assessment visit 
and final dosing visit will be tabulated. Frequency of dose adjustment and duration of treatment 
interruption due to Hgb >13.0 g/dL will be summarized. 
 
9.4.4.2. 
Adverse Events 
All AEs will be categorized by the MedDRA system organ class and preferred term to tabulate the 
number and incidence. All AEs, SAEs, AEs leading to discontinuation of study treatment, and AEs of 
special interest will be summarized separately. Similar summary will be provided for study treatment-
related AEs.  
 
9.4.4.3. 
Other Safety Parameters 
For laboratory tests, vital signs and ECG, parameters and/or changes from baseline will be 
summarized using summary statistics at each assessment visit. The number and percentage of subjects 
with values of the potential clinical importance values will be tabulated. The criteria for the potential 
clinical importance will be described in the RAP. For lipid parameters (total cholesterol, LDL 
cholesterol, and HDL cholesterol), percent changes will also be tabulated. The number (%) of subjects 
who have any change in anti-hypertensive medications (type and/or dose) due to increased blood 
pressure will be tabulated. 
 
9.4.5. 
Pharmacokinetics Analyses 
For plasma concentrations of daprodustat over time, individual data will be listed, and summary 
statistics at each time point will be calculated for each dose level. For PK parameters (AUC 0-4 and 
Cmax), summary statistics will be calculated for each dose level, and scatter plots against the dose 
level will be generated.  
 
9.4.6. 
PRO Data Analysis 
Details of PRO data tabulation will be described in the RAP. 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
51 
 
10. STUDY GOVERNANCE CONSIDERATIONS 
10.1. Posting of Information on Publicly Available Clinical Trial Registers 
Study information from this protocol will be posted on publicly available clinical trial registers before 
enrollment of subjects begins. 
 
10.2. Regulatory and Ethical Considerations, Including the Informed Consent 
Process 
The study will be conducted in accordance with “the Ministerial Ordinance on the Standards for the 
Conduct of Clinical Trials of Medicinal Products (MHW Notification No.28 dated 27th March, 1997)” 
and the Pharmaceutical Affairs Law. 
 
GSK will submit the CTN to the regulatory authorities in accordance with with Article 80-2 of the 
Pharmaceutical Affairs Law before conclusion of any contract for the conduct of the study with study 
sites. 
 
The study will be conducted in accordance with all applicable regulatory requirements, and with GSK 
policy. 
The study will also be conducted in accordance with ICH Good Clinical Practice (GCP), all applicable 
subject privacy requirements, and the guiding principles of the current version of the Declaration of 
Helsinki.  This includes, but is not limited to, the following: 
• 
IRB/IEC review and favorable opinion/approval of the study protocol and amendments as 
applicable 
• 
Signed informed consent to be obtained for each subject before participation in the study (and for 
amendments as applicable)  
• 
Investigator reporting requirements (e.g. reporting of AEs/SAEs/protocol deviations to IRB/IEC) 
• 
GSK will provide full details of the above procedures, either verbally, in writing, or both. 
• 
The IEC/IRB, and where applicable the regulatory authority, approve the clinical protocol and all 
optional assessments, including genetic research.   
• 
Optional assessments (including those in a separate protocol and/or under separate informed 
consent) and the clinical protocol should be concurrently submitted for approval unless 
regulation requires separate submission.   
• 
Approval of the optional assessments may occur after approval is granted for the clinical protocol 
where required by regulatory authorities.  In this situation, written approval of the clinical 
protocol should state that approval of optional assessments is being deferred and the study, with 
the exception of the optional assessments, can be initiated. 
 
Informed Consent 
Prior to participation in the study, the investigator (or subinvestigator) should fully inform the 
potential subject and the subject's legally acceptable representative (as required) of the study including 
the written information. The investigator (or subinvestigator) should provide the subject and the 
subject's legally acceptable representative ample time and opportunity to inquire about details of the 
study. The subject and the subject’s legally acceptable representative should sign and personally date 
the consent form. If the subject wishes to consider the content of the written information at home, 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
52 
 
he/she may take the consent form home. The person who conducted the informed consent discussion 
and study collaborator giving supplementary explanation, where applicable, should sign and 
personally date the consent form. If an impartial witness is required, the witness should sign and 
personally date the consent form. The investigator (or subinvestigator) should retain this signed and 
dated form (and other written information) together with the source medical records, such as clinical 
charts (in accordance with the rules for records retention, if any, at each medical institution) and give a 
copy to the subject and the subject’s legally acceptable representative. 
 
10.3. Quality Control (Study Monitoring) 
• 
In accordance with applicable regulations including GCP, and GSK procedures, GSK monitors 
will contact the site prior to the start of the study to review with the site staff the protocol, study 
requirements, and their responsibilities to satisfy regulatory, ethical, and GSK requirements.   
• 
When reviewing data collection procedures, the discussion will also include identification, 
agreement and documentation of data items for which the CRF will serve as the source 
document. 
 
GSK will monitor the study and site activity to verify that the: 
• 
Data are authentic, accurate, and complete. 
• 
Safety and rights of subjects are being protected. 
• 
Study is conducted in accordance with the currently approved protocol and any other study 
agreements, GCP, and all applicable regulatory requirements. 
• 
 
The investigator and the head of the medical institution (where applicable) agrees to allow the monitor 
direct access to all relevant documents 
 
10.4. Quality Assurance 
• 
To ensure compliance with GCP and all applicable regulatory requirements, GSK may conduct a 
quality assurance assessment and/or audit of the site records, and the regulatory agencies may 
conduct a regulatory inspection at any time during or after completion of the study.  
• 
In the event of an assessment, audit or inspection, the investigator (and institution) must agree to 
grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and to 
allocate their time and the time of their staff to discuss the conduct of the study, any 
findings/relevant issues and to implement any corrective and/or preventative actions to address 
any findings/issues identified. 
 
10.5. Study and Site Closure 
• 
Upon completion or premature discontinuation of the study, the GSK monitor will conduct site 
closure activities with the investigator or site staff, as appropriate, in accordance with applicable 
regulations including GCP, and GSK Standard Operating Procedures. 
• 
GSK reserves the right to temporarily suspend or prematurely discontinue this study at any time 
for reasons including, but not limited to, safety or ethical issues or severe non-compliance. For 
• 
multicenter studies, this can occur at one or more or at all sites. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
53 
 
• 
If GSK determines such action is needed, GSK will discuss the reasons for taking such action 
with the investigator or the head of the medical institution (where applicable). When feasible, 
GSK will provide advance notification to the investigator or the head of the medical institution, 
where applicable, of the impending action. 
• 
If the study is suspended or prematurely discontinued for safety reasons, GSK will promptly 
inform all investigators, heads of the medical institutions (where applicable) and/or institution(s) 
conducting the study. GSK will also promptly inform the relevant regulatory authorities of the 
suspension or premature discontinuation of the study and the reason(s) for the action.   
• 
If required by applicable regulations, the investigator or the head of the medical institution 
(where applicable) must inform the IRB/IEC promptly and provide the reason for the suspension 
or premature discontinuation. 
 
10.6. Records Retention 
• 
Following closure of the study, the investigator or the head of the medical institution (where 
applicable) must maintain all site study records (except for those required by local regulations to 
be maintained elsewhere), in a safe and secure location. 
• 
The records must be maintained to allow easy and timely retrieval, when needed (e.g., for a GSK 
audit or regulatory inspection) and must be available for review in conjunction with assessment 
of the facility, supporting systems, and relevant site staff. 
• 
Where permitted by local laws/regulations or institutional policy, some or all of these records can 
be maintained in a format other than hard copy (e.g., microfiche, scanned, electronic); however, 
caution needs to be exercised before such action is taken.  
• 
The investigator must ensure that all reproductions are legible and are a true and accurate copy of 
the original and meet accessibility and retrieval standards, including re-generating a hard copy, if 
required. Furthermore, the investigator must ensure there is an acceptable back-up of these 
reproductions and that an acceptable quality control process exists for making these 
reproductions. 
• 
GSK will inform the investigator of the time period for retaining these records to comply with all 
applicable regulatory requirements. The minimum retention time will meet the strictest standard 
applicable to that site for the study, as dictated by any institutional requirements or local laws or 
regulations, GSK standards/procedures, and/or institutional requirements.   
• 
The investigator must notify GSK of any changes in the archival arrangements, including, but not 
limited to, archival at an off-site facility or transfer of ownership of the records in the event the 
investigator is no longer associated with the site. 
 
10.7. Provision of Study Results to Investigators, Posting of Information on 
Publically Available Clinical Trials Registers and Publication 
Where required by applicable regulatory requirements, an investigator signatory will be identified for 
the approval of the clinical study report. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the complete 
study results at a GSK site or other mutually-agreeable location. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
54 
 
GSK will also provide the investigator with the full summary of the study results. The investigator is 
encouraged to share the summary results with the study subjects, as appropriate. 
 
GSK will also provide the investigator with the randomization numbers assigned to the subjects of 
his/her study site after the completion of all analyses. 
 
The procedures and timing for public disclosure of the results summary and for development of a 
manuscript for publication will be in accordance with GSK Policy. 
 
10.8. Study Period 
See Exhibit 1 
 
10.9. Study Administrative Structure 
Sponsor information is included in Exhibit 2. List of Medical Institutions and Investigators is included 
in Exhibit 3. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
55 
 
11. REFERENCES 
Akizawa T, Makino H, Matsuo S, et al. Management of anemia in chronic kidney disease patients: 
baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol. 2011;15:248-
57. 
Szczech LA, Barnhart HX., Inrig JK., et al. Secondary analysis of the CHOIR trial epoetin-α dose and 
achieved hemoglobin outcomes. Kidney International. 2008;74:791-8. 
Guidelines for Renal Anemia in Chronic Kidney Disease issued by the Japanese Society for Dialysis 
Therapy in 2015. Journal of Japanese Society for Dialysis Therapy. 2016;49(2):89-158 
 
MIRCERA. Product information in Europe (methoxy polyethylene glycol-epoetin beta). 2012-May. 
2012. 
 
KDIGO. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney 
International Supplement. 2012 Aug;2(4): 279-335. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
- 56 - 
12. APPENDICES 
12.1. Appendix 1: Abbreviations and Trademarks 
 
Abbreviations 
ALT 
Alanine Aminotransferase 
AST 
Aspartate Aminotransferase 
AUC 
Area Under Curve 
CKD 
Chronic Kidney Disease 
Cmax 
Maximum concentration 
CPK 
Creatine Phosphokinase 
CYP 
Cytochrome P450 
DNA 
Deoxyribonucleic Acid 
EPO 
Erythropoietin 
EQ-5D-5L 
EuroQol EuroQol 5 Dimension 5 Level Health Utility Index 
EQ-VAS 
EuroQol Visual Analogue Scale  
ESA 
Erythropoiesis-Stimulating Agent 
FDA 
Food and Drug Administration 
FSH 
Follicle Stimulating Hormone 
GCP 
Good Clinical Practice 
GSK 
GlaxoSmithKline 
hCG 
Human Chorionic Gonadotrophin 
HD 
Hemodialysis 
HDL 
High Density Lipoprotein 
HDF 
Hemodiafiltration 
Hgb 
Hemoglobin 
HIF 
Hypoxia-Inducible Factor 
HRQoL 
Health Related Quality of Life 
HRT 
Hormone Replacement Therapy 
ICH 
International Conference on Harmonization 
INR 
International Normalized Ratio 
iPTH 
Intact Parathyroid Hormone  
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Recognition System 
LDH 
Lactate Dehydrogenase 
LDL 
Low Density Lipoprotein  
MCS 
Mental Component Summary  
MCH 
Mean Corpuscular Hemoglobin 
MCHC 
Mean Corpuscular Hemoglobin Concentration 
MCV 
Mean Corpuscular Volume 
MedDRA 
Medical Dictionary for Regulatory Activities 
mITT 
modified Intent-to-Treat 
NYHA 
New York Heart Association 
PAH 
Pulmonary Artery Hypertension 
PCS 
Physical Component Summary 
PD 
Peritoneal Dialysis 
PHI 
Prolyl Hydroxylase Inhibitor 
PK 
Pharmacokinetic 
PP 
Per-Protocol 
PRO 
Patient Reported Outcome 
QT Interval 
Q-T Interval 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
- 57 - 
QTc Interval 
Q-T Interval Corrected for Heart Rate 
QTcB 
Bazett’s Correction of QT Interval 
RAP 
Reporting and Analysis Plan 
RDW 
Red Blood Cell Distribution Width 
RNA 
Ribonucleic Acid 
rhEPO 
Recombinant human erythropoietin 
SAE 
Serious Adverse Event  
sPAP 
Systolic Pulmonary Artery Pressure 
SRM 
Study Reference Manual 
TIBC 
Total Iron Binding Capacity 
TSAT 
Transferrin Saturation 
UIBC 
Unsaturated iron Binding Capacity 
VAS 
Visual Analog Scale  
VEGF 
Vascular Endothelial Growth Factor 
 
Trademark Information 
Trademarks of the GlaxoSmithKline group of 
companies 
 
Trademarks not owned by the GlaxoSmithKline 
group of companies 
None 
 
Hemocue 
 
 
NespⓇ 
 
 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 58 - 
12.2. Appendix 2:  Risk Assessment 
 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
Daprodustat  
Excessive erythropoiesis (polycythemia) leading to 
thrombosis and/or tissue ischemia 
In animal studies, excessive erythropoiesis attributed to daprodustat 
was associated with vascular congestion, microthrombi, and tissue 
ischemia in a number of organs. 
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat. 
Phase 2 dose-ranging studies, and associated statistical and 
exposure response modelling has informed Phase 3 dose 
rationale, starting doses, dose levels, and dose adjustment 
scheme to optimize Hgb management. 
• 
Specific eligibility criteria related to requirements 
for entry Hgb are detailed in Section 5.1. 
• 
Hgb will be closely monitored 
throughout the dosing period as 
outlined in the Time and Events Table 
Section 7.1. 
• 
Specific guidance for dose adjustment, 
dose interruption, or discontinuation of 
daprodustat based on achieved Hgb is 
provided in Section 6.4.1. 
• 
These risks have been identified as AEs 
of special interest and will be 
monitored instreamly by the internal 
safety review team throughout the 
study period. 
Death, MI, stroke, heart failure, thromboembolic events, 
thrombosis of vascular access at Hgb levels which are 
within the normal range (i.e. not polycythemic conditions) 
Marketed rhEPO/ESAs have been associated with an increased risk for 
death and serious cardiovascular events when used in patients with 
anemia of CKD. 
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat. 
• 
Specific eligibility criteria related to CV risk are 
outlined in Section 5.2. 
• 
Hgb will be closely monitored 
throughout the dosing period as 
outlined in the Time and Events Table 
Section 7.1. 
• 
These risks have been identified as AEs 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 59 - 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
of special interest and will be 
monitored instreamly by the internal 
safety review team throughout the 
study period. 
Esophageal and gastric erosions 
In animal studies, undesirable GI effects including emesis, abnormal 
feces and/or decreased food consumption/body weight loss and 
stomach erosions/ ulcers with hemorrhage were observed.   
In rodents stomach erosions observed with intravenous and oral 
administration of daprodustat. 
Gender-averaged systemic exposure (AUC) at the no observed 
adverse effect levels (NOAEL) are 3.3 -fold (monkeys) and 737 
-fold (rats) above human exposure (25 mg). 
In clinical trials to date, mild-moderate GI signs and symptoms 
represent the most frequently reported adverse event, however 
causal association has not been established. 
Following review of clinical data received to date, GI erosions 
have not been identified as a safety concern for daprodustat. 
• 
Suspected GI bleeding or significant symptoms 
consistent with erosion should be investigated 
diagnostically (i.e. endoscopic examination) as 
clinically warranted 
• 
These risks have been identified as AEs 
of special interest and will be 
monitored instreamly by the internal 
safety review team throughout the 
study period. 
Cancer-related mortality, tumor progression and recurrence 
In clinical trials, use of rhEPO in patients with cancer has been 
associated with increased risk of cancer related morbidity and 
mortality. 
Administration of 60 mg/kg daprodustat to mice caused minimal 
increases in circulating VEGF while significant EPO increases were 
observed. 
In clinical studies up to 4 weeks duration, a dose-ordered increase in 
VEGF plasma concentrations, an angiogenic factor that has been 
implicated in tumor growth, was observed at doses ranging from 10 to 
150 mg. In clinical studies up to 24 weeks duration at doses up to 
25 mg, changes in VEGF plasma concentrations were variable but 
similar relative to control. 
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat.  
• 
Specific eligibility criteria related to personal history 
of malignancy are outlined in Section 5.2.. 
• 
Stopping criteria for subjects with 
treatment emergent malignancy are 
outlined in Section 5.4. 
• 
These risks have been identified as AEs 
of special interest and will be 
monitored instreamly by the internal 
safety review team throughout the 
study period. 
Pulmonary artery hypertension (PAH) 
A role for HIF-regulated pathways in the pathophysiology of PAH has been 
suggested based on well established effects of acute and chronic hypoxia in 
• 
These risks have been identified as AEs of special 
interest and will be monitored instreamly by the 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 60 - 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
man on the pulmonary vasculature (vasoconstriction), and by findings in 
patients with naturally occurring mutations that result in decreased HIF 
degradation (Smith, 2006; Formenti, 2011). 
 
There have been no histopathologic findings suggestive of PAH in pre-clinical 
safety studies (up to 13-weeks duration in mice and dog, up to 26-weeks in rat, 
and up to 39-weeks in monkeys. 
 
Acute hypoxic challenge (rats): daprodustatA produced increases in peak right 
ventricular pressure (PRVP) during acute hypoxia that were slightly higher 
than the vehicle control group. These hypoxia-induced PRVP changes fall 
within the range of PRVP differences noted among non-treated rats. 
 
Results from a clinical study of acute hypoxic challenge in healthy volunteers 
demonstrated that short-term therapy with daprodustat 5 mg or 100 mg has no 
clinically significant effect on echocardiographically estimated pulmonary 
artery systolic pressure (PASP) under either normoxic or hypoxic conditions. 
 
ECHO assessments performed in Phase 2b studies (24 weeks treatment 
duration) did not identify any clinically meaningful changes in sPAP in subjects 
not on dialysis. In hemodialysis subjects, mean absolute change from baseline 
in sPAP was similar for both treatment groups; however, there was a numeric 
imbalance (GSK Total: 8 [7%]; Control 0) in subjects reaching the sPAP PCI 
(>20 mmHg increase from baseline). Regarding this imbalance, there were a 
number of confounding factors in the study, most notably a 4.5:1 
randomization scheme and inconsistency in timing of ECHOs relative to 
dialysis day.  Additionally, 2 of 3 subjects with resolution of sPAP on safety 
follow-up ECHOs had confounding conditions that could contribute to 
resolution other than discontinuation of study treatment; and there was no 
dose relationship for subjects meeting the sPAP PCI criterion. Overall, there is 
insufficient evidence to conclude a relationship to treatment with daprodustat. 
 
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat. 
internal safety review team throughout the study 
period. 
Cardiomyopathy 
Published data suggest that cardiac effects of HIF stabilization are likely a 
function of the mechanism, extent, and duration of the effects, and can range 
from protective to detrimental depending upon the specific model and 
experimental conditions utilized. 
• 
These risks have been identified as AEs of special 
interest and will be monitored instreamly by the 
internal safety review team throughout the study 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 61 - 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
Small increases in cardiac troponin in 6 month rat study were 
consistent with the background finding of spontaneous rodent 
cardiomyopathy. There were no elevations observed in cardiac 
troponin in 9 month monkey study. 
Cardiomyopathy has not been associated with naturally 
occurring mutation in man which results in increased HIF 
stabilization. 
ECHO assessments performed in phase 2b studies (24 weeks treatment 
duration) did not identify any clinically meaningful changes in LVEF. 
 
Following review of clinical data received to date, this has not been identified 
as a safety concern for daprodustat. 
period. 
Proliferative retinopathy, macular edema, choroidal 
neovascularization 
Increases in local (ocular) VEGF production with retinal 
neovascularization and macular edema observed in diabetic 
retinopathy and to choroidal leakage, edema and neovascularization 
seen in age-related macular degeneration (Campochiaro, 2006). 
Administration of 60 mg/kg daprodustat to mice caused 
minimal increases in circulating VEGF while significant EPO 
increases were observed. 
No ocular abnormalities were seen in non-clinical studies of up 
to 13 weeks duration in mice and dogs, 26 weeks in rats, and 
39-weeks in monkeys.   
In clinical studies up to 4 weeks duration, a dose-ordered increase in 
VEGF plasma concentrations was observed at doses ranging from 10 
to 150 mg. In studies up to 24 weeks duration at doses up to 25 mg, 
changes in VEGF plasma concentrations were variable but similar 
relative to control. 
Ophthalmologic assessments performed in phase 2b studies (24 
weeks treatment duration) did not identify any clinically 
meaningful changes in proliferative retinopathy, macular 
edema, or choroidal neovascularization. 
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat. 
• 
Ophthalmology exams will be performed during 
screening, at approximately Week 12 on-study, and 
at the end of treatment. 
• 
These risks have been identified as AEs 
of special interest and will be 
monitored instreamly by the internal 
safety review team throughout the 
study period.  
• 
Suspected proliferative retinopathy, 
macular edema, choroidal 
neovascularization or symptoms 
consistent with these events should be 
investigated by ophthalmologic 
consultation as clinically warranted. 
Exacerbation of rheumatoid arthritis 
In inflamed rheumatic joints, activation of HIF- related genes 
• 
These risks have been identified as AEs of special 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 62 - 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
secondary to decreased oxygen and pro-inflammatory cytokines has 
been postulated to contribute to the neo-angiogenesis, proliferation and 
infiltration of rheumatoid synovial fibroblasts (Westra, 2010; Muz, 
2009). 
No abnormalities seen in non-clinical studies conducted to date. 
Following review of clinical data received to date, this has not 
been identified as a safety concern for daprodustat. 
interest and will be monitored instreamly by the 
internal safety review team throughout the study 
period. 
Drug-drug interactions 
Co-administration of daprodustat with a strong CYP2C8 inhibitor 
increased the Cmax and AUC of daprodustat, 4- and 19-fold, 
respectively, while co-administration of a weak inhibitor increased the 
Cmax and AUC of daprodustat by 1.3- and 1.5-fold, respectively. 
Population PK analysis from completed Phase 2 studies suggests that 
co-administration of daprodustat with a moderate CYP2C8 inhibitor, 
leads to a ~ 2-fold increase in AUC, with no clinically-significant 
increase in the measured Hgb response. 
Daprodustat is an inhibitor of CYP2C8 in vitro, with an IC50 
value of 21 µM. 
Population PK analysis from completed Phase 2 studies 
suggests that co-administration of daprodustat with clopidogrel 
(a moderate CYP2C8 inhibitor) leads to a ~ 2-fold increase in 
AUC, with no clinically-significant increase in the measured 
Hgb response. Co-administration of daprodustat with moderate 
CYP2C8 inhibitors (i.e., clopidogrel, teriflunomide, 
deferasirox) should be performed with caution.  
Co-administration of daprodustat with potent BCRP inhibitors 
has the potential to increase exposure of daprodustat. Use of 
BCRP inhibitors (mostly weak) was found to result in a small 
change in metabolite exposure (20% increase in AUC). 
Daprodustat is an inhibitor of OATP1B1/1B3 in vitro, with IC50 
values of 6 µM and 11 µM, respectively. A clinical drug 
interaction study between 25mg daprodustat with either a 
CYP2C8 substrate or an OATP1B1/1B3 substrate showed that 
there is no PK interaction at this dose of daprodustat. 
Co-administration of daprodustat with strong 
CYP2C8 inhibitors (e.g., gemfibrozil) and inducers 
(e.g., rifampin/rifampicin) is not permitted as 
outlined in Section 6.11.2. 
Co-administration of daprodustat with 
moderate CYP2C8 inhibitors (i.e., clopidogrel, 
teriflunomide, deferasirox) should be 
performed with caution.  
Specific guidance on the management of 
potential drug-drug interactions and 
concomitant medications is provided in 
Section 6.11. 
• 
Hgb will be closely monitored throughout the 
dosing period as outlined in the Time and Events 
Table Section 7.1. 
Specific guidance for dose adjustment, dose 
interruption, or discontinuation of daprodustat based 
on achieved Hgb is provided in Section 6.4.1. 
Safety data will be monitored instreamly by 
the internal safety review team throughout the 
study period. 
Other 
ESA risks (Control) 
See risks outlined in table for daprodustat for Excessive erythropoiesis 
The same mitigation strategies have been indentified 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 63 - 
Potential Risk of Clinical Significance 
Summary of Data/Rationale for Risk 
Mitigation Strategy 
(polycythemia) leading to thrombosis and/or tissue ischemia; Risk of 
MI, stroke, thromboembolic events, thrombosis of vascular access; and 
risk of cancer-related mortality and tumor progression. 
 
Uncontrolled hypertension. 
 
Pure red cell aplasia 
 
Hepatic function disorder with increase of ALT and Gamma-
glutamyltransferase, and jaundice have been reported as adverse 
drug reactions according to the prescribing information of 
darbepoetin alfa. 
in acoordance with the mitigation strategies for 
daprodustat  
Monitor instreamly blood pressure throughout 
the study as scheduled in Table 10. 
Specific eligibility criteria related to personal 
history of pure red cell aplasia are outlined in 
Section 5.2. 
Liver function will be monitored throughout 
the dosing period as outlined in the Time and 
Events Table provided in Section 7.1. 
 
References 
Campochiaro PA and the First ARVO/Pfizer Institute Working Group. Ocular versus Extraocular Neovascularization: Mirror Images or Vague Resemblances. 
Invest Ophthalmol & Vis Sci. 2006;47:462-74. 
 
Formenti F, Beer PA, Croft QP, et al. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau 
disease and HIF-2alpha gain-of-function mutation. FASEB J. 2011;25(6):2001-11. 
 
Muz B, Khan MN, Kiriakidis S, et al. Hypoxia.The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Research & 
Therapy. 2009;11:201. 
 
Smith TG, Brooks JT, Balanos GM, et al. Mutation of von Hippel-Lindau Tumour Suppressor and Human Cardiopulmonary Physiology . PLoS Med. 
2006;3:1178-86. 
 
Westra J, Molema G and Kallenberg CG. Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications.  
Current Medicinal Chemistry 2010;17(3):254-63.  

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 64 - 
 
12.3. Appendix 3: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in Females of reproductive potential 
This list does not apply to FRP with same sex partners, when this is their preferred and usual lifestyle 
or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long 
term and persistent basis. 
1. 
Contraceptive subdermal implant that meets the Prescribing Information effectiveness criteria 
including a <1% rate of failure per year, as stated in the Prescribing Information  
2. 
Intrauterine device or intrauterine system that meets the Prescribing Information effectiveness 
criteria including a <1% rate of failure per year, as stated in the Prescribing Information 
[Hatcher, 2011] 
3. 
Combined estrogen and progestogen oral contraceptive [Hatcher, 2011]  
4. 
Injectable progestogen [Hatcher, 2011] 
5. 
Contraceptive vaginal ring [Hatcher, 2011] 
6. 
Percutaneous contraceptive patches [Hatcher, 2011] 
7. 
Male partner sterilization with documentation of azoospermia prior to the female subject's entry 
into the study, and this male is the sole partner for that subject [Hatcher, 2011].   
 
These allowed methods of contraception are only effective when used consistently, correctly and in 
accordance with the Prescribing Information. The investigator is responsible for ensuring that subjects 
understand how to properly use these methods of contraception. 
 
References 
Trussell J, Contraceptive Efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, and 
Policar M (editors). Contraceptive Technology: Twentieth Revised Edition. New York: Ardent Media, 
2011. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 65 - 
 
12.4. Appendix 4: Collection of Pregnancy Information 
• 
Investigator will collect pregnancy information on any female subject, who becomes pregnant 
while participating in this study 
• 
Information will be recorded on the appropriate form and submitted to GSK within 2 weeks of 
learning of a subject's pregnancy. 
• 
Subject will be followed to determine the outcome of the pregnancy. The investigator will collect 
follow up information on mother and infant, which will be forwarded to GSK. Generally, follow-
up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date.  
• 
Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of 
anomalies) or indication for procedure. 
• 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. 
• 
A spontaneous abortion is always considered to be an SAE and will be reported as such.   
• 
Any SAE occurring as a result of a post-study pregnancy which is considered reasonably related 
to the study treatment by the investigator, will be reported to GSK as described in Section 12.6. 
Appendix 6. While the investigator is not obligated to actively seek this information in former 
study participants, he or she may learn of an SAE through spontaneous reporting. 
 
Any female subject who becomes pregnant while participating 
• 
will discontinue study medication or be withdrawn from the study 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 66 - 
 
12.5. Appendix 5: Liver Safety Required Actions and Follow up Assessments 
Phase III-IV liver chemistry stopping and increased monitoring criteria have been designed to 
assure subject safety and evaluate liver event etiology (in alignment with the FDA premarketing 
clinical liver safety guidance). 
 
Phase III-IV liver chemistry stopping criteria and required follow up assessments 
Liver Chemistry Stopping Criteria - Liver Stopping Event 
ALT-absolute 
ALT ≥ 8xULN 
ALT Increase 
ALT ≥ 5xULN but <8xULN  persists for ≥2 weeks 
ALT ≥ 3xULN but <5xULN  persists for ≥4 weeks 
Bilirubin1, 2 
ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% direct bilirubin)  
INR2  
ALT ≥ 3xULN and INR>1.5, if INR measured 
Cannot 
Monitor 
ALT ≥ 5xULN but <8xULN and cannot be monitored weekly for ≥2 weeks 
ALT ≥ 3xULN but <5xULN and cannot be monitored weekly for ≥4 weeks 
Symptomatic3 
ALT  ≥ 3xULN associated with symptoms (new or worsening) believed to be related to  
liver injury or hypersensitivity 
Required Actions and Follow up Assessments following ANY Liver Stopping Event 
Actions 
Follow Up Assessments 
• 
Immediately discontinue study treatment  
• 
Report the event to GSK within 24 hours 
• 
Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2 
• 
Perform liver event follow up assessments  
• 
Monitor the subject until liver chemistries 
resolve, stabilize, or return to within baseline 
(see MONITORING below) 
• 
Do not restart/rechallenge subject with 
study treatment unless allowed per protocol 
and GSK Medical Governance approval is 
granted  
• 
If restart/rechallenge not allowed or not 
granted, permanently discontinue study 
treatment and may continue subject in the 
study for any protocol specified follow up 
assessments  
• 
 
MONITORING: 
For bilirubin or INR criteria:  
• 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
• 
Viral hepatitis serology4 
• 
Only in those with underlying chronic 
hepatitis B at study entry (identified by 
positive hepatitis B surface antigen) and 
quantitative hepatitis B DNA  
• 
Blood sample for pharmacokinetic (PK) 
analysis, obtained within 24 hours after last 
dose5 
• 
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH). 
• 
Fractionate bilirubin, if total 
bilirubin≥2xULN 
• 
Obtain complete blood count with 
differential to assess eosinophilia 
• 
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form 
• 
Record use of concomitant medications on 
the concomitant medications report form 
including acetaminophen, herbal remedies, 
other 
• 
 over the counter medications. 
• 
Record alcohol use on the liver event 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 67 - 
 
liver event follow up assessments within 24 
hrs 
• 
Monitor subjects twice weekly until liver 
chemistries resolve, stabilize or return to 
within baseline 
• 
A specialist or hepatology consultation is 
recommended 
For All other criteria:  
• 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  
24-72 hrs  
• 
Monitor subjects weekly until liver 
chemistries resolve, stabilize or return to 
within baseline 
alcohol intake case report form 
For bilirubin or INR criteria: 
• 
Anti-nuclear antibody, anti-smooth muscle 
antibody, Type 1 anti-liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG or gamma 
globulins). 
• 
Serum acetaminophen adduct HPLC assay 
(quantifies potential acetaminophen 
contribution to liver injury in subjects with 
definite or likely acetaminophen use in the 
preceding week [James, 2009]). 
• 
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy CRF forms. 
1. 
Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT ≥ 3xULN and bilirubin ≥ 2xULN.  
2. 
All events of ALT ≥ 3xULN and bilirubin ≥ 2xULN (>35% direct bilirubin) or ALT ≥ 3xULN and INR>1.5, if 
INR measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold 
value stated will not apply to subjects receiving anticoagulants 
3. 
New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)    
4. 
Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody or Hepatitis E RNA 
5. 
PK sample may not be required for subjects known to be receiving placebo or non-GSK comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to 
blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in the 
time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in the 
SRM.   
 
 
Phase III-IV liver chemistry increased monitoring criteria with continued therapy 
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event 
Criteria 
Actions 
 
ALT ≥5xULN and <8xULN and bilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2 weeks. 
OR 
• 
Notify the GSK medical monitor within 24 hours 
of learning of the abnormality to discuss subject 
safety.  
• 
Subject can continue study treatment   
• 
Subject must return weekly for repeat liver 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 68 - 
 
ALT ≥3xULN and <5xULN and bilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4 weeks. 
 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline  
• 
If at any time subject meets the liver chemistry 
stopping criteria, proceed as described above 
• 
If ALT decreases from ALT ≥5xULN and 
<8xULN to ≥3xULN but <5xULN, continue to 
monitor liver chemistries weekly.  
• 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor subjects twice monthly 
until liver chemistries normalize or return to 
within baseline. 
 
References 
James LP, Letzig L, Simpson PM, et al. Pharmacokinetics of Acetaminophen-Protein Adductsin 
Adults with Acetaminophen Overdose and Acute Liver Failure. Drug Metab Dispos. 2009;37:1779-84. 
 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 69 - 
 
12.6. Appendix 6: Definition of and Procedures for Recording, Evaluating, Follow-
Up and Reporting of Adverse Events 
12.6.1. 
Definition of Adverse Events 
Adverse Event Definition: 
• 
An AE is any untoward medical occurrence in a patient or clinical investigation subject, 
temporally associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. 
• 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use 
of a medicinal product. 
 
Events meeting AE definition include: 
• 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (e.g., ECGs, radiological scans, vital signs measurements), including those 
that worsen from baseline, and felt to be clinically significant in the medical and scientific 
judgement of the investigator. 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition. 
• 
New conditions detected or diagnosed after study treatment administration even though it may 
have been present prior to the start of the study. 
• 
Signs, symptoms, or the clinical sequelae of a suspected interaction. 
• 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication (overdose per se will not be reported as an AE/SAE unless this is an 
intentional overdose taken with possible suicidal/self-harming intent.  This should be reported 
regardless of sequelae). 
• 
"Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as 
an AE or SAE.  However, the signs and symptoms and/or clinical sequelae resulting from lack 
of efficacy will be reported if they fulfil the definition of an AE or SAE. 
 
Events NOT meeting definition of an AE include: 
• 
Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by the investigator to be more 
severe than expected for the subject’s condition. 
• 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s condition. 
• 
Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the 
procedure is an AE. 
• 
Situations where an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital). 
• 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected 
at the start of the study that do not worsen. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 70 - 
 
12.6.2. 
Definition of Serious Adverse Events 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are 
met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of 
disease, etc). 
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: 
a. 
Results in death 
b. 
Is life-threatening 
NOTE: 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at 
risk of death at the time of the event.  It does not refer to an event, which hypothetically might have 
caused death, if it were more severe. 
c. 
Requires hospitalization or prolongation of existing hospitalization 
NOTE: 
• 
In general, hospitalization signifies that the subject has been detained (usually involving at least 
an overnight stay) at the hospital or emergency ward for observation and/or treatment that would 
not have been appropriate in the physician’s office or out-patient setting.  Complications that 
occur during hospitalization are AEs.  If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious.  When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious. 
• 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
d. 
Results in disability/incapacity 
NOTE: 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute 
a substantial disruption 
e. 
Is a congenital anomaly/birth defect 
f. 
Other situations: 
• 
Medical or scientific judgment should be exercised in deciding whether reporting is appropriate 
in other situations, such as important medical events that may not be immediately life-threatening 
or result in death or hospitalization but may jeopardize the subject or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above definition.  These 
should also be considered serious. 
• 
Examples of such events are invasive or malignant cancers, intensive treatment in an emergency 
room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization, or development of drug dependency or drug abuse 
g. 
Is associated with liver injury and impaired liver function defined as: 
• 
ALT ≥ 3xULN and total bilirubin* ≥ 2xULN (>35% direct), or 
• 
ALT ≥ 3xULN and INR** > 1.5. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 71 - 
 
* Serum bilirubin fractionation should be performed if testing is available; (for ND patients only) if 
unavailable, record presence of detectable urinary bilirubin on dipstick, indicating direct bilirubin 
elevations and suggesting liver injury. If fractionation is unavailable and ALT ≥ 3xULN and total 
bilirubin ≥ 2xULN, then the event is still to be reported as an SAE. 
** INR testing not required per protocol and the threshold value does not apply to subjects receiving 
anticoagulants.  If INR measurement is obtained, the value is to be recorded on the SAE form. 
 
 
12.6.3. 
Definition of Cardiovascular Events 
Cardiovascular Events (CV) Definition: 
Investigators will be required to fill out the specific CV event page of the CRF for the following AEs 
and SAEs: 
• 
Myocardial infarction/unstable angina 
• 
Congestive heart failure 
• 
Arrhythmias 
• 
Valvulopathy 
• 
Pulmonary hypertension 
• 
Cerebrovascular events/stroke and transient ischemic attack 
• 
Peripheral arterial thromboembolism 
• 
Deep venous thrombosis/pulmonary embolism 
• 
Revascularization 
 
12.6.4. 
Recording of AEs and SAEs 
AEs and SAE Recording: 
• 
When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(e.g., hospital progress notes, laboratory, and diagnostics reports) relative to the event. 
• 
The investigator will then record all relevant information regarding an AE/SAE in the CRF 
• 
It is not acceptable for the investigator to send photocopies of the subject’s medical records to 
GSK in lieu of completion of the GSK, AE/SAE CRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by GSK.  
In this instance, all subject identifiers, with the exception of the subject number, will be blinded 
on the copies of the medical records prior to submission of to GSK. 
• 
The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information.  In such cases, the diagnosis will be documented as the 
AE/SAE and not the individual signs/symptoms. 
• 
PRO questionnaires and the collection of AE data are independent components of the study. 
• 
Responses to each question in PRO questionnaire will be treated in accordance with standard 
scoring and statistical procedures detailed by the scale’s developer. 
• 
The use of a single question from a multidimensional health survey to designate a cause-effect 
relationship to an AE is inappropriate. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 72 - 
 
12.6.5. 
Evaluating AEs and SAEs 
Assessment of Intensity 
The investigator will make an assessment of intensity for each AE and SAE reported during the study 
and will assign it to one of the following categories: 
• 
Mild:  An event that is easily tolerated by the subject, causing minimal discomfort and not 
interfering with everyday activities. 
• 
Moderate:  An event that is sufficiently discomforting to interfere with normal everyday 
activities 
• 
Severe:  An event that prevents normal everyday activities. - an AE that is assessed as severe 
will not be confused with an SAE. Severity is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe. 
• 
An event is defined as ‘serious’ when it meets at least one of the pre-defined outcomes as 
described in the definition of an SAE. 
 
Assessment of Causality 
• 
The investigator is obligated to assess the relationship between study treatment and the 
occurrence of each AE/SAE. 
• 
A "reasonable possibility" is meant to convey that there are facts/evidence or arguments to 
suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other 
risk factors, and the temporal relationship of the event to the study treatment will be considered 
and investigated. 
• 
The investigator will also consult the Investigator Brochure (IB) and/or Product Information, for 
marketed products, in the determination of his/her assessment. 
• 
For each AE/SAE the investigator must document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality. 
• 
There may be situations when an SAE has occurred and the investigator has minimal information 
to include in the initial report to GSK.  However, it is very important that the investigator 
always make an assessment of causality for every event prior to the initial transmission of 
the SAE data to GSK. 
• 
The investigator may change his/her opinion of causality in light of follow-up information, 
amending the SAE data collection tool accordingly. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
• 
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by GSK to elucidate as 
fully as possible the nature and/or causality of the AE or SAE. 
• 
The investigator is obligated to assist.  This may include additional laboratory tests or 
investigations, histopathological examinations or consultation with other health care 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 73 - 
 
professionals. 
• 
If a subject dies during participation in the study or during a recognized follow-up period, the 
investigator will provide GSK with a copy of any post-mortem findings, including 
histopathology. 
• 
New or updated information will be recorded in the originally completed CRF. 
• 
The investigator will submit any updated SAE data to GSK within the designated reporting time 
frames. 
 
12.6.6. 
Reporting of SAEs to GSK 
SAE reporting to GSK via electronic data collection tool 
• 
Primary mechanism for reporting SAEs to GSK will be the electronic data collection tool 
• 
If the electronic system is unavailable for greater than 24 hours, the site will use the paper SAE 
data collection tool and fax it to the SAE contact. 
• 
Site will enter the serious adverse event data into the electronic system as soon as it becomes 
available. 
• 
The investigator (or subinvestiagtor) will mark a check against ‘reviewed’ box in the lower part 
of the eCRF page within 72 hours after reporting of SAE to ensure that the causality of AE has 
been reviewed. 
• 
After the study is completed at a given site, the electronic data collection tool (e.g., InForm 
system) will be taken off-line to prevent the entry of new data or changes to existing data 
• 
If a site receives a report of a new SAE from a study subject or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off-line, the site 
can report this information on a paper SAE form or to the SAE contact by telephone. 
• 
Contacts for SAE receipt can be found at the beginning of this protocol on the Sponsor/Medical 
Monitor Contact Information page. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 74 - 
 
12.7. Appendix 7 - Genetic Research  
Background 
Naturally occurring genetic variation may contribute to inter-individual variability in response to 
medicines, as well as an individual's risk of developing specific diseases. Genetic factors associated 
with disease characteristics may also be associated with response to therapy, and could help to explain 
some clinical study outcomes. For example, genetic variants associated with age-related macular 
degeneration (AMD) are reported to account for much of the risk for the condition [Gorin, 2012] with 
certain variants reported to influence treatment response [Chen, 2012]. Thus, knowledge of the genetic 
etiology of disease may better inform understanding of disease and the development of medicines. 
Additionally, genetic variability may impact the pharmacokinetics (absorption, distribution, 
metabolism, and elimination), or pharmacodynamics (relationship between concentration and 
pharmacologic effects or the time course of pharmacologic effects) of a specific medicine and/or 
clinical outcomes (efficacy and/or safety) observed in a clinical study. 
 
Genetic Research Objectives and Analyses 
The objective of the genetic research is to understand the response to daprodustat. To achieve this 
objective, the relationship between genetic variants and the followings may be investigated. 
• 
Response to medicine, including daprodustat, ESA, other study medicines or any concomitant 
medicines; 
• 
Nephrogenic anemia and related conditions susceptibility, severity, and progression  
• 
 
Genetic data may be generated while the study is underway or following completion of the study.  
Genetic evaluations may include focused candidate gene approaches and/or examination of a large 
number of genetic variants throughout the genome (whole genome analyses). Genetic analyses which 
will be conducted for this study will utilize data collected in the study and will be limited to 
understanding the objectives highlighted above. Analyses may be performed using data from multiple 
clinical studies related to daprodustat to investigate these research objectives. 
 
Appropriate descriptive and/or statistical analysis methods will be used. A detailed description of any 
planned analyses will be documented in a Reporting and Analysis Plan (RAP) prior to initiation of the 
analysis. Planned analyses and results of genetic investigations will be reported either as part of the 
clinical RAP and study report, or in a separate genetics RAP and report, as appropriate. 
 
Study Population 
Any subject who is enrolled in the study can participate in the genetic research. Any subject who has 
received an allogeneic bone marrow transplant must be excluded from the genetic research. 
 
Study Assessments and Procedures 
A key component of successful genetic research is the collection of samples during clinical studies. 
Collection of samples, even when no a priori hypothesis has been identified, may enable future 
genetic analyses to be conducted, align with the purpose of the genetic research, to help understand 
variability in disease and medicine response.   

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 75 - 
 
 
• 
A 6 mL blood sample will be taken for DNA extraction. A Blood sample is collected at the 
baseline visit, after the subject has been randomized and provided informed consent for genetic 
research. Instructions for collection and shipping of the genetic sample are described in the 
laboratory manual. The DNA from the blood sample may undergo quality control analyses to 
confirm the integrity of the sample. If there are concerns regarding the quality of the sample, then 
the sample may be destroyed. The blood sample is taken on a single occasion unless a duplicate 
sample is required due to an inability to utilize the original sample.   
 
The genetic sample is labelled (or “coded”) with the same study specific number used to label other 
samples and data in the study. This number can be traced or linked back to the subject by the 
investigator or site staff. Coded samples do not carry personal identifiers (such as name or social 
security number).  
 
Samples will be stored securely and may be kept for up to 15 years after the last subject completes the 
study, or GSK may destroy the samples sooner. GSK or those working with GSK (for example, other 
researchers) will only use samples collected from the study for the purpose stated in this protocol and 
in the informed consent form. Samples may be used as part of the development of a companion 
diagnostic to support the GSK medicinal product. 
 
Subjects can request their sample to be destroyed at any time. 
 
Informed Consent 
Subjects who do not wish to participate in the genetic research may still participate in the study.  
Genetic informed consent must be obtained prior to any blood being taken. 
 
Subject Withdrawal from Study 
If a subject who has consented to participate in genetic research withdraws from the clinical study for 
any reason other than being lost to follow-up, the subject will be given a choice of one of the 
following options concerning the genetic sample, if already collected: 
 
• 
Continue to participate in the genetic research in which case the genetic DNA sample is retained 
• 
Discontinue participation in the genetic research and destroy the genetic DNA sample  
 
If a subject withdraws consent for genetic research or requests sample destruction for any reason, the 
investigator must complete the appropriate documentation to request sample destruction within the 
timeframe specified by GSK and maintain the documentation in the site study records.  
 
Genotype data may be generated during the study or after completion of the study and may be 
analyzed during the study or stored for future analysis.  
 
• 
If a subject withdraws consent for genetic research and genotype data has not been analyzed, it 
will not be analyzed or used for future research.   

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 76 - 
 
• 
Genetic data that has been analyzed at the time of withdrawn consent will continue to be stored 
and used, as appropriate. 
• 
 
Screen and Baseline Failures 
If a sample for genetic research has been collected and it is determined that the subject does not meet 
the entry criteria for participation in the study, then the investigator should instruct the subject that 
their genetic sample will be destroyed. No forms are required to complete this process as it will be 
completed as part of the consent and sample reconciliation process. In this instance a sample 
destruction form will not be available to include in the site files. 
 
Provision of Study Results and Confidentiality of Subject’s Genetic Data 
GSK may summarize the genetic research results in the clinical study report, or separately and may 
publish the results in scientific journals.  
 
GSK may share genetic research data with other scientists to further scientific understanding in 
alignment with the informed consent. GSK does not inform the subject, family members, insurers, or 
employers of individual genotyping results that are not known to be relevant to the subject’s medical 
care at the time of the study, unless required by law. This is due to the fact that the information 
generated from genetic studies is generally preliminary in nature, and therefore the significance and 
scientific validity of the results are undetermined. Further, data generated in a research laboratory may 
not meet regulatory requirements for inclusion in clinical care. 
 
References 
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age-Related Macular Degeneration 
(AMD) Susceptibility Gene CFH and Treatment Response of AMD: A Meta-Analysis. PloS One 
2012;7:e42464. 
 
Gorin MB. Genetic insights into age-related macular degeneration: Controversies addressing risk, 
causality, and therapeutics. Mol. Aspects. Med. 2012;33:467-86. 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 77 - 
 
12.8. Appendix 8: Definition of and Procedures for Documenting Medical Device 
Incidents 
12.8.1. 
Definitions of a Medical Device Incident 
 
The detection and documentation procedures described in this protocol apply to all medical devices 
provided for use in the study (see Section 6.2 for the list of the medical devices). 
 
Medical Device Incident Definition: 
• 
Incident – Any malfunction or deterioration in the characteristics and/or performance of a device, 
as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, 
might lead to or might have led to the death of a patient/user/other persons or to a serious 
deterioration in their state of health. 
• 
Not all incidents lead to death or serious deterioration in health.  The non-occurrence of such a 
result might have been due to other fortunate circumstances or to the intervention of health care 
personnel. 
 
It is sufficient that: 
• 
an incident associated with a device happened and 
• 
the incident was such that, if it occurred again, might lead to death or a serious deterioration in 
health. 
A serious deterioration in state of health can include: 
• 
life-threatening illness 
• 
permanent impairment of body function or permanent damage to a body structure 
• 
a condition necessitating medical or surgical intervention to prevent one of the above  
• 
fetal distress, fetal death or any congenital abnormality or birth defects 
 
Examples of incidents 
• 
a patient, user, care giver or professional is injured as a result of a medical device failure or its 
misuse 
• 
a patient’s treatment is interrupted or compromised by a medical device failure 
• 
misdiagnosis due to medical device failure leads to inappropriate treatment 
• 
a patient’s health deteriorates due to medical device failure 
• 
 
12.8.1.1. 
Documenting Medical Device Incidents 
Medical Device Incident Documenting: 
• 
Any medical device incident occurring during the study will be documented in the subject’s 
medical records, in accordance with the investigator’s normal clinical practice, and on the 
appropriate form. 
• 
For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE CRF page 
will be completed as described in Appendix 6 (Section 12.6). 
• 
The form will be completed as thoroughly as possible and signed by the investigator before 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 78 - 
 
transmittal to GSK. 
• 
It is very important that the investigator provides his/her assessment of causality to the medical 
device provided by GSK at the time of the initial report, and describes any corrective or remedial 
actions taken to prevent recurrence of the incident. 
• 
A remedial action is any action other than routine maintenance or servicing of a device where 
such action is necessary to prevent recurrence of an incident. This includes any amendment to the 
design to prevent recurrence. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 79 - 
 
12.9. Appendix 9: Protocol Changes 
12.9.1. 
Amendment 1 － Summary of Changes and Rationale 
This is applicable to all study sites. 
 
List of Protocol Changes with Rationale for Each 
 
Sponsor Signatory: 
Original Text: 
Hiromu Nakajima 
Head, 
Medicines Development, 
Japan Development and Medical Affairs (JDMA), 
GlaxoSmithKline K. K. 
 
Revised Text: 
Kihito Takahashi 
Director 
Japan Development and Medical Affairs (JDMA), 
GlaxoSmithKline K. K. 
 
Reason: 
To reflect change of Sponsor Signatory. 
 
 
Emergency Contact 
Original Text: 
Emergency Contact at night and holiday (Mon to Fri 6pm to 10am, Sat, Sun, national holiday and 
year-end and New Year holidays) 
Bell Medical Solutions Inc. 
 
Revised Text: 
Emergency Contact at night and holiday (Mon to Fri 6pm to 10am, Sat, Sun, national holiday and 
year-end and New Year holidays) 
BI Medical Inc. 
 
Reason: 
To reflect change of company name. 
 
Exclusion Criteria 
Original Text: 
8. 
Liver disease (if any of the following occurs): 
• 
ALT > 2 x upper limit of normal (ULN) 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 80 - 
 
• 
Bilirubin > 1.5 x ULN (If bilirubin fractions are measured and direct bilirubin is < 35%, 
isolated bilirubin > 1.5 x ULN will be acceptable.) 
 
Revised Text: 
8. 
Liver disease (if any of the following occurs): 
• 
(Screening verification only): ALT > 2 x upper limit of normal (ULN) 
• 
(Screening verification only): Bilirubin > 1.5 x ULN (If bilirubin fractions are measured and 
direct bilirubin is < 35%, isolated bilirubin > 1.5 x ULN will be acceptable.) 
 
Reason: 
To clarify the timing of eligibility assessment regarding exclusion criteria. 
 
 
6.11.2. 
Prohibited Medications and Non-Drug Therapies 
Original Text: 
None 
 
Revised Text: 
Use of the following drug; during the treatment period: 
• 
Erythropoietin (e.g., epoetin/ darbepoetin alfa/ epoetin beta pegol) 
 
Note: excluding darbepoetin alfa (brand name: Nesp) supplied by GSK. 
 
Reason: 
To clarify that there is a limitation to use erythropoietin. 
 
 
7.1. 
Time and Events Table 
Original Text: 
Unless otherwise specified, all assessments should occur before dialysis on the day. 
 
Revised Text: 
In any case, the study visit should occur on the first dialysis session day of the week. Unless otherwise 
specified, all assessments should occur before dialysis on the day. 
 
Reason: 
To clarify study procedure. 
 
 
7.4.2. 
Adverse Events of Special Interest 
Original Text: 
• 
Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 81 - 
 
• 
Death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular 
access 
• 
Cardiomyopathy 
• 
Pulmonary artery hypertension (PAH) 
• 
Cancer-related mortality and tumor progression and recurrence  
• 
Esophageal and gastric erosions 
• 
Proliferative retinopathy, macular edema, choroidal neovascularization  
• 
Exacerbation of inflammatory joint disease (e.g., rheumatoid arthritis) 
 
Revised Text: 
• 
Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis 
• 
Death, myocardial infarction (MI), stroke, congestive heart failure, venous thromboembolism, 
thrombosis of vascular access 
• 
Cardiomyopathy 
• 
Pulmonary artery hypertension (PAH) 
• 
Cancer-related mortality and tumor progression and recurrence  
• 
Esophageal and gastric erosions 
• 
Proliferative retinopathy, macular edema, choroidal neovascularization  
• 
Exacerbation of rheumatoid arthritis 
 
Reason: 
To edit to correct text. 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 82 - 
 
12.9.2. 
Amendment 2 － Summary of Changes and Rationale 
This is applicable to all study sites. 
 
List of Protocol Changes with Rationale for Each 
 
1. 
PROTOCOL SYNOPSIS FOR STUDY PHI201754 
Analysis 
Original Text: 
As a preliminary assessment, it will be confirmed if the mean Hgb in daprodustat group would lie 
fully within target range (10.0-12.0 g/dL) at first. 
 
Revised Text: 
As a preliminary assessment, it will be confirmed if the lower and upper limit of 95% CI for mean 
Hgb during the primary efficacy evaluation period in daprodustat group would lie fully within target 
range (10.0-12.0 g/dL) at first. 
 
Reason: 
To adjust description. 
 
 
1 
PROTOCOL SYNOPSIS FOR STUDY PHI201754 
Analysis 
Original Text: 
None 
 
Revised Text: 
Following sensitivity analyses will be conducted to assess robustness of study result.  
• 
If there are Hgb considered to be impacted by blood transfusion or marketed rhEPO/ESAs, 
sensitivity analysis excluding the Hgb values from the analyses of primary endpoint will be 
conducted. 
• 
Analysis of covariance (ANCOVA) will be conducted as sensitivity analysis to MMRM. This 
model includes treatment group and baseline Hgb. The analysis population will be mITT 
population and the similar analysis will be repeated in the PP population. 
• 
A tipping point analysis based on multiple imputation will be conducted as sensitivity analysis to 
missing data assumption. This analysis explores a point where non-inferiority is not confirmed 
(tipping point) by changing assumption to missing data and repeating imputation. The analysis 
population will be ITT population and the similar analysis will be repeated in the mITT and PP 
population. 
 
Reason: 
To add sensitivity analyses for primary efficacy analyses and to adjust description. 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 83 - 
 
5.3. 
Screening Failures 
Original Text: 
Screen failures are defined as subjects who consent to participate in the clinical trial and are screened, 
but are not subsequently officially enrolled in the study. 
 
Revised Text: 
Screen failures are defined as subjects who consent to participate in the clinical trial, but are not 
subsequently officially enrolled in the study. 
 
Reason: 
To change the definition of screening failures. 
 
 
5.4. 
Permanent discontinuation of study treatment and study withdrawal 
Original Text: 
• 
Need for chronic (more than 14 days) use of prohibited medication 
 
Revised Text: 
• 
Need for chronic (more than 14 days) use of prohibited medication (strong inhibitors/ inducers of 
CYP2C8 meet this criteria) 
 
Reason: 
To clarify discontinuation criteria (prohibited medication). 
 
6.9. 
Treatment of Study Treatment Overdose 
Original Text: 
None 
 
Revised Text: 
For the purposes of this study, an overdose of daprodustat is defined as any dose greater than the 
highest daily dose included in the protocol. 
 
Reason: 
To clarify the definition of overdose of daprodustat. 
 
 
7.4.2. 
Adverse Events of Special Interest 
Original Text: 
• 
Death, myocardial infarction, stroke, congestive heart failure, venous thromboembolism, 
thrombosis of vascular access 
 
Revised Text: 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 84 - 
 
• 
Death, myocardial infarction, stroke, heart failure, thromboembolic events, thrombosis of 
vascular access 
 
Reason: 
To update AESI. 
 
9.1. 
Hypotheses 
Original Text: 
As a preliminary assessment, it will be confirmed whether the mean Hgb during the primary efficacy 
evaluation period in daprodustat group would be in target range (10.0-12.0 g/dL) at first. 
 
Revised Text: 
As a preliminary assessment, it will be confirmed whether the lower and upper limit of 95% CI for 
mean Hgb during the primary efficacy evaluation period in daprodustat group would be within target 
range (10.0-12.0 g/dL) at first. 
 
Reason: 
To adjust description. 
 
 
9.3.3. 
Adjustment for Multiplicity 
Original Text: 
Since the process will follow step-down manner, a multiplicity adjustment for significance level of 5% 
will not be needed according to a closed test procedure.  
Other secondary endpoints, which will be evaluated on a complementary or exploratory basis, will be 
compared at a significance level of 5% without multiplicity adjustment. 
 
Revised Text: 
Since the process will follow step-down manner, a multiplicity adjustment will not be needed 
according to a closed test procedure, similarly two-sided significance level of 5% will be used.  
Other secondary endpoints, which will be evaluated on a complementary or exploratory basis, will be 
compared at a two-sided significance level of 5% without multiplicity adjustment. 
 
Reason: 
To adjust description. 
 
 
9.4.1. 
Primary Efficacy Analysis 
Original Text: 
None 
 
Revised Text: 
Following sensitivity analyses will be conducted to assess robustness of study result.  

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 85 - 
 
• 
If there are Hgb considered to be impacted by blood transfusion or marketed rhEPO/ESAs, 
sensitivity analysis excluding the Hgb values from the analyses of primary endpoint will be 
conducted. 
• 
Analysis of covariance (ANCOVA) will be conducted as sensitivity analysis to MMRM. This 
model includes treatment group and baseline Hgb. The analysis population will be mITT 
population and the similar analysis will be repeated in the PP population. 
• 
A tipping point analysis based on multiple imputation will be conducted as sensitivity analysis to 
missing data assumption. This analysis explores a point where non-inferiority is not confirmed 
(tipping point) by changing assumption to missing data and repeating imputation. The analysis 
population will be ITT population and the similar analysis will be repeated in the mITT and PP 
population. 
 
Reason: 
To add sensitivity analyses for primary efficacy analyses. 
 
 
12.1. 
Appendix 1: Abbreviations and Trademarks 
Trademark Information 
Trademarks not owned by the GlaxoSmithKline group of companies 
Original Text: 
None 
 
Revised Text: 
NespⓇ 
 
Reason: 
To adjust description. 
 
 
12.2. 
Appendix 2: Risk Assessment 
Potential Risk of Clinical Significance 
Original Text: 
Death, MI, stroke, congestive heart failure, venous thromboembolism, thrombosis of vascular access 
at Hgb levels which are within the normal range (i.e. not polycythemic conditions) 
 
Revised Text: 
Death, MI, stroke, heart failure, thromboembolic events, thrombosis of vascular access at Hgb levels 
which are within the normal range (i.e. not polycythemic conditions) 
 
Reason: 
To update summary of clinical significant potential risk. 
 
 

2015N266251_02 
CONFIDENTIAL 
 
 
 
PHI201754 
 
- 86 - 
 
12.2. 
Appendix 2: Risk Assessment 
Potential Risk of Clinical Significance 
Pulmonary artery hypertension (PAH) 
Summary of Data/Rationale for Risk 
Original Text: 
Results from a clinical study of acute hypoxic challenge in healthy volunteers demonstrated that short-
term therapy with daprodustat 5 mg or 10 mg has no clinically significant effect on 
echocardiographically estimated pulmonary artery systolic pressure (PASP) under either normoxic or 
hypoxic conditions. 
 
Revised Text: 
Results from a clinical study of acute hypoxic challenge in healthy volunteers demonstrated that short-
term therapy with daprodustat 5 mg or 100 mg has no clinically significant effect on 
echocardiographically estimated pulmonary artery systolic pressure (PASP) under either normoxic or 
hypoxic conditions. 
 
Reason: 
To correct erroneous description. 
 
 
12.2. 
Appendix 2: Risk Assessment 
Potential Risk of Clinical Significance 
ESA risks (Control) 
Summary of Data/Rationale for Risk 
Original Text: 
See risks outlined in table for daprodustat for Excessive erythropoiesis (polycythemia) leading to 
thrombosis and/or tissue ischemia; Risk of MI, stroke, venous thromboembolism, thrombosis of 
vascular access; and risk of cancer-related mortality and tumor progression. 
 
Revised Text: 
See risks outlined in table for daprodustat for Excessive erythropoiesis (polycythemia) leading to 
thrombosis and/or tissue ischemia; Risk of MI, stroke, thromboembolic events, thrombosis of vascular 
access; and risk of cancer-related mortality and tumor progression. 
 
Reason: 
To update summary of data/rationale for risk.